

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-073425
Article Type:	Protocol
Date Submitted by the Author:	08-Mar-2023
Complete List of Authors:	liu, bin; Medical School of Chinese PLA; Chinese PLA General Hospital Xu, Junpeng; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yang, Haonan; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yu, Xinguang; Chinese PLA General Hospital, Department of Neurosurgery Mao, Zhiqi; Chinese PLA General Hospital, Department of Neurosurgery
Keywords:	Neurosurgery < SURGERY, Adult surgery < SURGERY, Adult neurology < NEUROLOGY



 Title: PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

(Version 1.0, 2023.03.03)

Authors: Bin Liu^{1, 2†}, Junpeng Xu^{1, 2†}, Haonan Yang^{1, 2}, Xinguang Yu^{2, *}, Zhiqi Mao^{2, *}

Affiliation:

¹ Medical School of Chinese PLA, Beijing, China

² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China

* Corresponding author:

Zhiqi Mao, MD, Department of Neurosurgery, the First Medical Center of Chinese PLA

General Hospital, Beijing, China, 100853

E-mail: markmaoqi@163.com

Xinguang Yu, MD, Department of Neurosurgery, the First Medical Center of Chinese

PLA General Hospital, Beijing, China, 100853

E-mail: yuxinguang_301@163.com

† These authors have contributed equally to this work

ABSTRACT

Introduction Deep brain stimulation (DBS) has been validated as a safe and effective treatment for refractory cervical dystonia (CD). Globus pallidus internus (GPi) and subthalamic nucleus (STN) are two main stimulating targets. However, there has been no prospective study to clarify which target is the better DBS candidate for CD. The objective of this trial is to compare directly the efficacy and safety of GPi-DBS and STN-DBS, thereby instructing the selection of DBS target in clinical practice.

Methods and analysis This multicenter, prospective, randomized, controlled study plans to enroll 98 refractory CD patients. Eligible CD patients will be randomly allocated to GPi-DBS group or STN-DBS group, with the DBS electrodes implanted into the posteroventral portion of GPi or the dorsolateral portion of STN, respectively. The primary outcome will be the improvement of symptomatic severity, measured by the changes of Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity subscale and Tsui scale at 1 month, 3 months, 6 months, and 12 months after surgery. The secondary outcomes include the improvement of TWSTRS-disability subscale, TWSTRS-pain subscale, quality of life, mental and cognitive condition, as well as the differences of stimulation parameters and adverse effects. In addition, this study intends to identify certain predictors of DBS efficacy for CD.

Ethics and dissemination The trial has been approved by the Medical Ethics Committee of Chinese PLA General Hospital (S2022-613-01). The results of this study will be published in international peer-reviewed journals and shared in professional medical conferences.

Trial registration numbers NCT05715138

Key Words cervical dystonia, deep brain stimulation, globus pallidus internus, subthalamic nucleus.

ARTICLE SUMMARY

Strengths and limitations of this study

The PASTS-CD study is the first randomized controlled study comparing the efficacy and safety of GPi-DBS and STN-DBS for cervical dystonia.

The primary outcomes are evaluated blindly through randomly shuffled, de-identified, standardized videos to minimize potential biases.

This trial uses the technique of imaging fusion to control the confounder of electrodes position, which is deemed to be the major influence factor of DBS efficacy.

One possible limitation is that investigators are not blinded because of the nature of surgical intervention.

INTRODUCTION

Background and rationale

Cervical dystonia (CD), also known as spasmodic torticollis, is a type of focal dystonia, mainly manifesting as involuntary head turning or tilting, or holding a prolonged and twisted posture.^{1, 2} CD limits the neck activity by involving one or a group of neck muscles and is often accompanied by pain and psychological disorders, seriously compromising patients' life quality.²

Medical treatment of CD is unsatisfactory. Oral medications are often ineffective or overshadowed by concomitant side effects.² Although most of CD patients can be alleviated by injection of botulinum toxin, the remission is temporary so that patients require multiple injections.³ Moreover, 25% of patients do not respond to botulinum toxin and 20%-40% of patients discontinued botulinum toxin treatment due to lack of benefit.^{4, 5} Denervation and myotomy of the involved muscles is an effective surgery for CD once, but it becomes powerless in face of complicated cases.⁶

Deep brain stimulation (DBS) has been substantiated to be a safe and effective therapy for primary CD, even for those medically refractory cases.⁷ The globus pallidus internus (GPi) was considered as the preferred DBS target for various types of dystonia (including CD) with remarkable short-term and long-term efficacy.⁷⁻¹⁶ In addition, stimulation of the subthalamic nucleus (STN) has drawn increasing attention in recent years with the superiorities of lower stimulation parameters requirement and shorter onset time. A series of studies have demonstrated that STN-DBS is a promising alternative to GPi-DBS, with a long-term symptomatic improvement rate ranging from 50% to 90%,¹⁷⁻²¹ similar to and even higher than that of GPi-DBS. For studies focusing on CD only, both GPi-DBS^{10, 22-27} and STN-DBS^{17, 28, 29} show significant therapeutic effect. However, the question of which nucleus is the better DBS candidate for CD has not been clarified.

Previous comparisons of both targets were mainly about dystonia as a whole (including focal, segmental, and generalized dystonia). There was a prospective crossover study directly comparing the efficacy and safety of GPi-DBS and STN-DBS by implanting two sets of DBS electrodes for each dystonic patient and stimulating alternately one of them.^{30, 31} The results seemed to favor STN-DBS at the 6-month follow-up,³⁰ but no significant between-group difference was found at the over ten-years follow-up.³¹ Furthermore, another crossover study evaluated the effect of 24-hour stimulation of either STN or GPi for eight dystonic patients and also found no significant between-group difference.³² Retrospectively, STN-DBS was proven to outperform GPi-DBS in terms of movement improvement at the 1-month follow-up, but this superiority disappeared later, and at the 12-month follow-up, GPi-DBS was more efficient than STN-DBS, relative to GPi-DBS, is associated with a better outcome in the univariate regression model but not in the multivariate model.³⁴ However, these studies did not distinguish specific phenotypes (not focus on CD). Additionally, the prospective studies were degraged by their small sample size and the retrospective analyses yielded inconsistent results.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

For CD specifically, there have been no prospective studies to compare GPi-DBS with STN-DBS. From a retrospective perspective, a meta-analysis comparatively analyzed the results of 13 relative studies, including 58 CD patients undergoing GPi-DBS and 28 CD patients undergoing STN-DBS.³⁵ They found that when the factor of follow-up time was not taken into account, the improvement rates of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) subscores (severity, disability, and pain) were all significantly higher in the GPi-DBS group than that in the STN-DBS group, though the TWSTRS total score was not significantly different. Nevertheless, when the follow-up time was limited within three years, neither TWSTRS total score nor subscores showed a significantly between-group difference.³⁵ Similarly, another meta-analysis also failed to detect any significant difference — the improvement rates of the TWSTRS total score were 60.4% (GPi-DBS) and 56.6% (STN-DBS), respectively (p=0.936).³⁶ However, the two meta-analyses included low-quality studies and showed significant heterogeneity and publication bias. Surgeons still have confusions in face of target selection before surgery. As such, a well-designed randomized controlled trial (RCT) is entailed to ascertain which one (STN or GPi) is the optimal DBS target for CD.

Objective

The PASTS-CD study aims to compare GPi-DBS with STN-DBS for drug-refractory CD in the following aspects: (1) improvement of dystonic symptoms (severity, disability, and pain), (2) improvement of life quality, mental status, and cognitive status, (3) stimulation parameters, (4)

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

adverse effects. In the end, the study intends to identify the potential factors that are associated with DBS efficacy in both groups.

METHODS AND ANALYSIS

Study design and setting

The PASTS-CD study is an investigator-initiated, multicenter, prospective, randomized, parallelcontrolled equivalence clinical trial, following the rules of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.³⁷ This study is composed of two paralleling arms with an allocation ratio of 1:1, both of which undergo the same procedures except for the difference in DBS target (GPi or STN). The flow chart of the trial is presented in figure 1. This study will be implemented from March 2023 to November 2026 in four tertiary hospitals in China. This study only incorporates hospitals that have been qualified in DBS surgery for more than 5 years with more than 20 DBS operations per year, and where DBS surgery-related complication rate is less than 5%. In addition, all investigators will go through a standardized training prior to trial initiation.

Participants

Recruitment

The investigators will post the recruitment announcement on the official website and WeChat account of each center. CD Patients who are willing to participate in the trial will visit the dystonic outpatient of each center.

Inclusion criteria

- (1) Diagnosed as idiopathic or hereditary isolated CD;
- (2) Severe functional impairment despite optimal medical management;
- (3) No secondary causes of CD;
- (4) Age 18-80 years old;
- (5) Normal neurological examination except for dystonia;
- (6) Normal brain MRI;
- (7) The subject or their family members can fully understand the trial and sign the informed consent;
- (8) Good compliance and willingness to receive regular follow-ups.

Exclusion criteria

- (1) Diagnosed as secondary CD;
- (2) CD with obvious trunk/limb involvement, or Meige syndrome;
- (3) History of severe mental disorders, dementia, or epilepsy;
- (4) Previous dystonia surgery (pallidotomy, thalamotomy, DBS, etc);
- (5) Accompanied by other neurological diseases (Parkinson's disease, essential tremor, multiple sclerosis, stroke, etc);
- (6) The patient has or needs other implantable devices (cardiac pacemakers, defibrillators, cochlear implants, spinal cord stimulators, etc);
- (7) Pregnant women or women who are waiting to become pregnant during the trial;
- (8) Poor health condition.

Dropout or suspension of the trial

- (1) Postoperative infection that requires removal of DBS electrodes;
- (2) Severe displacement of DBS electrodes position from the predefined targets (>3mm);
- (3) Occurrence of severe adverse events or other serious diseases that interfere the efficacy

(4) Loss to follow up;

(5) Requests from patients to withdraw from the trial;

Interventions

Baseline evaluation

For each eligible patient, the basic information, medical history, disease characteristics and medications will be recorded in the electronic medical record system in detail. Besides, physical examination, routine blood tests and MRI scanning are assigned before surgery. Every patient will be videotaped as per a standardized scheme (see supplementary material) at least 12 hours after drug withdrawal. This video will be collected to complete the TWSTRS-severtiy subscale and Tsui scale by two neurological raters blindly at the end of the trial. Moreover, TWSTRS-disability subscale, TWSTRS-pain subscale, 36-item Short Form General Health Survey (SF-36), Hamilton Anxiey Scale (HAMA), Hamilton Depression Scale (HAMD), Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) will also be completed before surgery. The timeline of data collection is shown in table 1. After signature of informed consent form, candidate patients will be randomized into GPi-DBS group or STN-DBS group.

DBS surgery

Certain minor differences in surgical procedures are allowed among involved centers, but some critical steps must keep in line with each other. Specifically, elaborate target/trajectory planning and precise image fusion of MRI and stereotactic CT scanning are warranted before surgery. According to the preference of each center, DBS electrodes can be implanted with the assistance of Leksell stereotactic frame or neurosurgical robot under local or general anesthesia. But microelectrode recording (MER) must be performed intraoperatively, even under general anesthesia — on recording, the dosage of propofol has to be reduce so as not to affect neuronal discharges.³⁸ According to the randomized allocation, the corresponding quadripolar electrodes will be implanted into posteroventral GPi (GPi-DBS group) or dorsolateral STN (STN-DBS group), bilaterally. The implanted electrodes can be selected from anyone of the following three manufacturers: Medtronic (Minneapolis, USA), PINS Medical (Beijing, China) and SceneRay (Suzhou, China). Of note, in light of the volume difference of the two nuclei, electrodes with contact intervals of 1.5mm are chosen for GPi-DBS, but 0.5mm for STN-DBS. Furthermore, given that patients' heads are immobilized by the frame, intraoperative macrostimulation is not recommended. Afterwards, inserted leads will be fixed at the burr hole site and a rechargeable or a non-rechargeable implantable pulse generator (IPG) will be connected and implanted at the right subclavicular area subcutaneously.

Electrode position confirmation

If possible, an intraoperative MRI scanning is strongly recommended to verify the implantation accuracy. Otherwise, a postoperative MRI or CT scanning is compulsory before discharge from hospital. Via the Lead-DBS software,³⁹ the investigators coregister and normalize the preoperative and postoperative images, and locate the four contacts in terms of the artifacts on the postoperative images. In order to exclude the effect of electrode position on the DBS efficacy, if the deviating distance between the sensorimotor subregion (according to DISTAL Minimal atlas)⁴⁰ and the nearest contact of the electrodes exceeds 3mm (STN-DBS group) or 5mm (GPi-DBS group), the subject will be dropped out.

Follow-up

One month later, the DSB will be activated by a specialized DBS programmer in the outpatient department. To evaluate stimulation effects and adverse effects of both electrodes, all contacts will be screened in a monopolar model with voltage increasing gradually from 1V to 4V and pulse width and frequency kept at 60us and 130Hz. The optimal parameters will be documented and used for chronic stimulation. After the DBS activation and at the 3-month follow-up, a standardized video will be recorded and TWSTRS-disability and pain subscales are completed by a centrally-trained rater. At the 6-month and 12-month follow-ups, besides the standardized video and TWSTRS subscales, all the other scales (i.e. SF-36, HAMA, HAMD, MMSE, and MoCA) will also be evaluated (table 1). Of note, botulinum toxin injection is forbidden during the follow-up period and the patient should stop taking oral medication for 12 hours before each evaluation. Furthermore, throughout the implementation of the trial, all adverse effects must be handled in safety and documented in detail, regardless of surgery-derived, device-related, or stimulation-induced events. The initial stimulating setting can be modulated at any time when the patients feel unsatisfactory about the symptom control or encounter a stimulation-induced adverse effect.

Outcome measurements

The primary outcomes are the changes (improvement rates) of TWSTRS-severity subscale and Tsui scale at 1 month, 3 months, 6 months, and 12 months after surgery. The reason why these two scales are chosen as the primary outcomes is that both of them are obtained from standardized videos, while the TWSTRS disability and pain subscales can be acquired via questionnaire (no need for a standardized video). The Tsui scale is a rational complement to the TWSTRS-severity subscale by adding the assessment of head tremor.

The secondary outcomes are the changes (improvement rates) of TWSTRS-disability subscale and TWSTRS-pain subscale, the difference of stimulation parameters and adverse effects at 1 month, 3 months, 6 months, and 12 months after surgery, as well as SF-36 questionnaire, HAMA scale, HAMD scale, MMSE scale, and MoCA scale at 6 months and 12 months after surgery. Stimulation parameters are mirrored by the total electrical energy delivered (TEED = voltage² * pulse width * frequency *1 second / impedance).⁴¹ The higher the TEED, the shorter the battery life of stimulator. The improvement rate of each scale can be calculated by the following formula: (score at each follow-up time point - baseline score) / baseline score *100%.

Tabel 1 Participant timeline of data collection.

	Enrolme nt	Allocatio n/Surgery	Post- Surgery		Follo	ow-up	
TIMEPOINT	-1	0	1	4	12	24	48
(weeks±1)							(Close-out)
ENROLMENT :							
Eligibility screen	Х						
Informed consent	Х						
Medical history	Х						
MRI scanning	Х		Х				
Allocation		Х					
INTERVENTIONS :							
GPi-DBS surgery		Х					
STN-DBS surgery		Х					
DBS				Х	Х	Х	Х

ASSESSMENTS :							
Standardized video*	Х			Х	Х	Х	Х
TWSTRS-disability	Х			Х	Х	Х	Х
TWSTRS-pain	Х			Х	Х	Х	Х
SF-36	Х					Х	Х
HAMA	Х					Х	Х
HAMD	Х					Х	Х
MMSE	Х					Х	Х
MoCA	Х					Х	Х
Medication	Х				Х	Х	Х
Stimulation parameters				Х	Х	Х	Х
Adverse effects		Х	Х	Х	Х	Х	Х

Sample size

The sample size is calculated based on one of the primary outcome — the improvement rate of TWSTRS-severity subscore. According to the results of the latest meta-analysis comparing GPi-DBS with STN-DBS for CD treatment, the improvement rates (%) of TWSTRS-severity subscore at the same follow-up time (3 years) were 53.7±20.4 (GPi-DBS) and 39.3±26.4 (STN-DBS), respectively.³⁵ Based on the model of two independent sample T test, 41 patients for each group are required to reach a significant level of 5% (two-tailed) with 80% power. Assuming that 5% CD patients would be withdrawn from the trial and another 10% CD patients would be lost to follow-up, a total of 98 CD patients are required (49 patients for each group).

Randomization and blinding

Randomization is achieved through a central randomization system connected by web. For instance, having obtained the consent from an eligible patient or his/her family, a neurosurgeon of each center will submit the basic information of the patient to the online system, and then a unique random code and grouping information (GPi-DBS group or STN-DBS group) will be returned automatically. Only this neurosurgeon has access to the central randomization system.

Investigators (mostly neurosurgeons) are not blinded because of the nature of surgical intervention, but patients, scale raters, and data analysts are blinded. At the time of scales scoring and videos recording, each patient wears an operating cap so that scale raters are blinded to the condition of surgery (preoperatively or postoperatively). All standardized videos recorded for evaluation of TWSTRS-severity subscale and Tsui scale will be shuffled randomly and scored centrally by two experienced neurologists who do not know the grouping information and time points of follow-up. Furthermore, before data is transferred to data analysts for statistical analysis, data manager will mask the grouping information and set two groups as A and B instead. Only when the subjects are withdrawn would they be unblinded.

Data collection and management

The schematic chart for data collection is shown in table 1. Prior to the enrollment of the first patient, all investigators (including neurosurgeons, coordinators, scale raters, DBS programmers, data manager, etc) have to receive standardized training about the data collection and management. At baseline and each follow-up time point, all information (medical history, scales, videos, programming parameters, and adverse effects) will be transferred to a coordinator who will then fill

in the case report forms (CRFs). All items in CRFs have to be completed and any correction should be noted and explained. Eventually, two coordinators upload the standardized videos and input the information of CRFs into the electronic data capture (EDC) system — Whole Course Management Service Platform (https://admin.demo.sdc.sinohealth.com/login).

Notably, the EDC system is embedded with a patient client that can be installed on patients' or their family's mobile phones, through which, investigators can push disease-related knowledge or questionnaires (for example, SF-36) to patients and conversely, patients can submit questionnaires and express their complaints to investigators at any time. Before each follow-up time point, patients will receive an alert from this client, thereby improving the follow-up compliance. For those withdrawn patients, the investigators also try to connect them and complete the 1-year follow-up.

During data collection, two data monitors will audit the contents of the CRFs to ensure data authenticity and accuracy. In addition, a data manager will review the EDC data online in real time and check the data consistency. Any data error or query existing, the data manager will send it back to the corresponding center where the investigators will check the original documents, answer the query, and update the data. At the end of the trial, the data manager will lock the EDC database and send the data to two data analysts for analysis.

All data files should be managed with great care and confidentiality. Only authorized investigators can log in the EDC system with password and any modification trace on the DEC platform will be preserved. Additionally, all original scale files and CRFs will be locked in a special cabinet and all video files will be stored in an encrypted folder.

Data monitor

Any adverse events during the study period should be documented in detail, including the information of event date, category, severity, treatment, and prognosis. If severe adverse events occur, the principal investigator must be notified within 24 hours.

Two study monitors who are independent of the implementation of this trial and have no competing interests will regularly visit the participating centers to inspect the protocol adherence, recruitment status, data collection, reporting of adverse events, and subject dropout rate. The monitoring results will be presented to the principal investigator and the local ethics committee. The interim analyses are unnecessary because plenty of previous studies have confirmed the safety of DBS surgery of both targets.^{7, 10, 14, 16, 17, 29} Herein, this trial only concentrates on their potential differences.

Statistical analysis

Outcome statistics will be performed using cases with complete data, i.e., per protocol (PP) analyses. In addition, for the primary outcomes, an intention-to-treat (ITT) analysis (including all patients assigned in the trial) will also be performed with missing values imputed by multiple interpolation. Continuous variables will be presented as means \pm standard deviations for normally distributed data or as medians (interquartile ranges) for skewed data. Categorical variables will be presented as frequencies or percentages. For difference analyses of baseline information, this study uses Wilcoxon rank-sum test for continuous variables and chi-square test or Fisher's exact test for categorical variables. Moreover, two-way ANOVA will be used to analyze the main effects (group or time) and the interaction effects. Within-group post hoc comparisons between different time points will be analyzed by paired T test or Wilcoxon signed-rank sum tests. Between-group comparisons at a certain time point will be analyzed using Wilcoxon rank-sum test. Factors associated with DBS efficacy, such as age at surgery and disease duration, will be included as covariates.^{31, 34, 42} Finally, to explore predictors of DBS outcomes, this study use simple linear

regression first to screen variables relevant to the improvement rates of TWSTRS, and multiple linear regression second to identify independent variables.

A difference of p < 0.05 (two-tailed) is specified as statistically significant. SPSS 26 statistical software will be used for statistical analyses.

ETHICS AND DISSEMINATION

The PASTS-CD trial protocol has been approved by the Medical Ethics Committee of Chinese PLA General Hospital (S2022-613-01), which is also responsible for re-examining protocol modifications in the future, if any. Moreover, this trial has been registered on Clinicaltrials.gov (NCT05715138).

The investigators have to explain every surgical details to the patients or their family, and the informed consent form must be signed before allocation. For those patients with surgical sequelae, this study provides ancillary and post-trial care according to standard medical practice.

The investigators have access to the final results, which will be published in international peerreviewed journals and shared in professional medical conferences. The raw data can be available from the corresponding author on reasonable request. Patients' information will be de-identified and videos will be mosaicked before exhibition.

DISCUSSION

To the best of our knowledge, the PASTS-CD study is the first prospective RCT study directly comparing the efficacy and safety of GPi-DBS and STN-DBS for refractory CD patients. The results of this trial will be a powerful guidance for neurosurgeons in selection of DBS target for CD patients. One notable advantage of this trial is that the primary outcomes are quantified by standardized videos centrally and blindly by two neurologists. The customized scheme of standardized video recording has been tested to suffice for the scoring of TWSTRS-severity subscale and Tsui scale. This design will eliminate the measurement bias from different scale raters of different centers and the interviewer bias from the subjectivity of scale raters. Another advantage is that this trial controls the confounding effect of electrode implantation accuracy, which is considered to be the most relevant factor to DBS efficacy.^{43, 44} Due to the small size of the subcortical nuclei and the complex surrounding structures, a minor deviation from the target will bring about a significant disparity in DBS efficacy and adverse effects. Through measuring the distance between the sensorimotor subregion of target nuclei and the contacts of electrodes, the investigators exclude those subjects in which the volume of tissue activated (VTA) of DBS electrodes are speculated to show no or a low overlapping with the sensorimotor subregion of target nuclei. According to previous experiences^{45,} ⁴⁶ and volume difference of the two targets, the cutoff distance is defined to be 3mm for STN-DBS group and 5mm for GPi-DBS group. This procedure also minimizing the influence of technical discrepancy of different neurosurgeons.

One possible limitation is that the neurosurgeons are not be blinded, but this is determined by the nature of surgical intervention. In fact, the main role of neurosurgeons is implanting the DBS electrodes into the predefined subregion of the two subcortical nuclei, and they do not participate in the subsequent scales scoring and DBS programming. As such, through controlling the accuracy of electrode position, the accompanying bias from the unblinded neurosurgeons will be significantly reduced. In addition, owing to the low incidence of CD, the investigators have to initiate a multicenter study to meet the requirement of sample size. Although multicenter studies may increase heterogeneity to some extent, it is believed that strict protocol implementation, coupled with systematic training and constant study monitoring, will help to minimize the biases and maximize

the reliability of results.

Author affiliations

¹ Medical School of Chinese PLA, Beijing, China

² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing,

China

Acknowledgements None

Contributors

Study conception: MZQ and YXG. Initial study design: LB and XJP. Revision of study design and protocol: MZQ. statistical analysis: YHN. Study coordination: YXG. Drafting the manuscript: LB and XJP. All authors read and approved the final manuscript.

Funding This trial is supported by STI 2030 - Major Projects (2021ZD0200407).

Competing interests None declared.

Patients and public involvement Patients and the public are not involved in the design and implementation of this trial.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

ORCID iD

Bin Liu <u>http://orcid.org/0000-0001-5114-7350</u> Zhiqi Mao http://orcid.org/0000-0002-8535-4531

References

1. Albanese A. Deep brain stimulation for cervical dystonia. Lancet Neurol 2014;13:856-7.

Crowner BE. Cervical dystonia: disease profile and clinical management. Phys Ther 2007;87:1511 Construction of the second second

3. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002;62:705-22.

4. Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol 2015;262:837-48.

5. Jinnah HA, Comella CL, Perlmutter J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 2018;147:89-95.

6. Ravindran K, Ganesh Kumar N, Englot DJ, et al. Deep Brain Stimulation Versus Peripheral Denervation for Cervical Dystonia: A Systematic Review and Meta-Analysis. World Neurosurg 2019;122:e940-e46.

7. Rodrigues FB, Duarte GS, Prescott D, et al. Deep brain stimulation for dystonia. Cochrane Database Syst Rev 2019;1:CD012405.

8. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459-67.

9. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-90.

BMJ Open

10. Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457-9.

11. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007;6:223-9.

12. Mueller J, Skogseid IM, Benecke R, et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord 2008;23:131-4.

 Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;11:1029-38.

14. Moro E, LeReun C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. Eur J Neurol 2017;24:552-60.

15. Meoni S, Fraix V, Castrioto A, et al. Pallidal deep brain stimulation for dystonia: a long term study. J Neurol Neurosurg Psychiatry 2017;88:960-67.

16. Krause P, Volzmann S, Ewert S, et al. Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years. J Neurol 2020;267:1622-31.

17. Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011;76:870-8.

18. Zhan S, Sun F, Pan Y, et al. Bilateral deep brain stimulation of the subthalamic nucleus in primary Meige syndrome. J Neurosurg 2018;128:897-902.

19. Ostrem JL, San Luciano M, Dodenhoff KA, et al. Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. Neurology 2017;88:25-35.

20. Deng Z, Pan Y, Zhang C, et al. Subthalamic deep brain stimulation in patients with primary dystonia: A ten-year follow-up study. Parkinsonism Relat Disord 2018;55:103-10.

21. Cao C, Pan Y, Li D, et al. Subthalamus deep brain stimulation for primary dystonia patients: a long-term follow-up study. Mov Disord 2013;28:1877-82.

22. Chung M, Huh R. Different clinical course of pallidal deep brain stimulation for phasic- and tonic-type cervical dystonia. Acta Neurochir (Wien) 2016;158:171-80; discussion 80.

23. Kaelin-Lang A, You H, Burgunder JM, et al. Bilateral pallidal stimulation improves cervical dystonia for more than a decade. Parkinsonism Relat Disord 2020;81:78-81.

24. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medicationrefractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014;13:875-84.

25. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007;130:2879-86.

26. Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013;136:761-9.

27. Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 2012;19:610-5.

28. Yin F, Zhao M, Yan X, et al. Bilateral subthalamic nucleus deep brain stimulation for refractory isolated cervical dystonia. Sci Rep 2022;12:7678.

29. Gupta A. Subthalamic stimulation for cervical dystonia. Acta Neurochir (Wien) 2020;162:1879-81.

30. Schjerling L, Hjermind LE, Jespersen B, et al. A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg 2013;119:1537-45.

31. Hock AN, Jensen SR, Svaerke KW, et al. A randomised double-blind controlled study of Deep

Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 years. Parkinsonism Relat Disord 2022;96:74-79.

32. Liu Y, Zhu G, Jiang Y, et al. Comparison of Short-Term Stimulation of the Globus Pallidus Interna and Subthalamic Nucleus for Treatment of Primary Dystonia. World Neurosurg 2019;123:e211-e17.

33. Lin S, Wu Y, Li H, et al. Deep brain stimulation of the globus pallidus internus versus the subthalamic nucleus in isolated dystonia. J Neurosurg 2019;132:721-32.

34. Wu YS, Ni LH, Fan RM, et al. Meta-Regression Analysis of the Long-Term Effects of Pallidal and Subthalamic Deep Brain Stimulation for the Treatment of Isolated Dystonia. World Neurosurg 2019;129:e409-e16.

35. Hua X, Zhang B, Zheng Z, et al. Predictive factors of outcome in cervical dystonia following deep brain stimulation: an individual patient data meta-analysis. J Neurol 2020;267:1780-92.

36. Tsuboi T, Wong JK, Almeida L, et al. A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia. J Neurol 2020;267:1278-90.

37. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.

38. Venkatraghavan L, Rakhman E, Krishna V, et al. The Effect of General Anesthesia on the Microelectrode Recordings From Pallidal Neurons in Patients With Dystonia. J Neurosurg Anesthesiol 2016;28:256-61.

39. Horn A, Kuhn AA. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. Neuroimage 2015;107:127-35.

40. Ewert S, Plettig P, Li N, et al. Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity. Neuroimage 2018;170:271-82.

41. Koss AM, Alterman RL, Tagliati M, et al. Calculating total electrical energy delivered by deep brain stimulation systems. Ann Neurol 2005;58:168; author reply 68-9.

42. Isaias IU, Volkmann J, Kupsch A, et al. Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration. J Neurol 2011;258:1469-76.

43. Wodarg F, Herzog J, Reese R, et al. Stimulation site within the MRI-defined STN predicts postoperative motor outcome. Mov Disord 2012;27:874-9.


44. Park HR, Lee JM, Ehm G, et al. Correlation of electrode position and clinical outcomes in globus pallidus stimulation for dystonia. Acta Neurochir (Wien) 2017;159:1349-55.

45. Zhang D, Lin H, Liu J, et al. Electrode Reconstruction Assists Postoperative Contact Selection in Deep Brain Stimulation. World Neurosurg 2019;125:e442-e47.

46. Astrom M, Diczfalusy E, Martens H, et al. Relationship between neural activation and electric field distribution during deep brain stimulation. IEEE Trans Biomed Eng 2015;62:664-72.

Figure legend

Figure 1 Flow chart of the PASTS-CD study. GPi, globus pallidus internus; STN, subthalamic nucleus; DBS, deep brain stimulation.



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

1

Scheme of Standardized Video Recording

1. Seated position. (The patient wears a surgical cap with head, neck and shoulders on camera.) ① Eyes closed (20 seconds: 10 seconds recorded from the front and 10 seconds from the side). Say to the patient, "Please sit down, close your eyes, and put your head where you feel most comfortable." ② Eyes open (10 seconds: 5 seconds recorded from the front and 5 seconds from the side). Say to the patient, "Please sit down, open your eyes, and try to look straight ahead and keep your head in the middle." ③ Turn head right and turn head left (5 seconds each) Say to the patient: "Look forward to the camera, turn your head to the right as far as you can, and then turn your head to the left as far as you can." ④ Head up and head down (5 seconds each) Say to the patient: "Look forward to the camera, raise your head as high as you can, and then lower your head as low as you can." ⑤ Put the ear close to the right shoulder and then the left shoulder (5 seconds each). Say to the patient, "Look forward to the camera. Now bring your right ear as close to your right shoulder as possible, and do not move your right shoulder." Say to the patient, "Look forward to the camera. Now bring your left ear as close to your left shoulder as possible, and do not move your left shoulder." ⁽⁶⁾ Symptom persistence Ask the patient, "If you divide your awake time during the day into four equal parts, how many parts do neck abnormalities take up?" (7) Symptom characteristics Ask the patient, "Does each episode come on suddenly or gradually?" (8) Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds) Say to the patient, "Please try to put your head in a straight position and look forward to the camera for one minute. Now start the clock." (9) Rest (10 seconds) Say to the patient, "Rest for 10 seconds." (1) Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds) Say to the patient, "Please do it again. Try to put your head in a straight position and look forward to the camera for one minute. Now start the clock." (11) Sensory tricks Say to the patient, "Are there some movements or postures you can do to straighten your head? If so, try to do it." 2. Standing position (Show the whole body) (1) Anterior view (5 seconds) Say to the patient, "Please stand up and face the camera." 2 Lateral view (5 seconds) Say to the patient, "Please turn 90 degrees to the left (or right)." 3. Walking (10 seconds) Say to the patient, "Please walk forward to the door and turn back."

Checklist

4 5 6 7			Reporting Item	Page Number
8 9 10 11	Administrative information			Pro
12 13 14	Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Title Page
15 16 17	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	1, 8 copyright
18 19 20 21	Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	n/a ncludin
22 23	Protocol version	<u>#3</u>	Date and version identifier	Title Page of
24 25	Funding	<u>#4</u>	Sources and types of financial, material, and other support	9 es re
26 27 28 29 30	Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	Title Page, 9 lated to text
31 32 33 34 35 36	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	Title Page1, 8n/an/aTitle Page9Title Page, 9Title Page, 9n/an/an/a(no sponsor)n/a(no sponsor)
37 38 39 40 41 42 43	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	and
44 45 46 47 48 49 50 51	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a technologies.
52 53	Introduction			
54 55 56 57 58	Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	1-2
59 60		For peer	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	1
5 6 7	Objectives	<u>#7</u>	Specific objectives or hypotheses	2-3
7 8 9 10 11 12 13	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	3
14	Methods:			
15	Participants,			
16 17	interventions, and			
18 19	outcomes			
20 21 22 23	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	3
24 25 26 27 28	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	3
29 30 31	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	4-5
32 33 34 35 36	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	4
37 38 39 40 41	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7
42 43 44	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	5
45 46 47 48 49 50 51 52 53	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	5
54 55 56 57 58	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-6
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
5 6 7 8	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	3
9 10 11 12 13 14	Methods: Assignment of interventions (for controlled trials)			
15 16 17 18 19 20 21 22	Allocation: sequence generation	<u>#16a</u>	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6
23 24 25 26 27 28 29	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6
30 31 32	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6
33 34 35 36 37	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	6
38 39 40 41 42	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	6
43 44 45 46 47 48	Methods: Data collection, management, and analysis			
49 50 51 52 53 54 55 56 57 58 59	Data collection plan	<u>#18a</u>	other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6, 6-7
60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7 BMJ Open:
5 6 7 8 9 10 11 12	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7BMJ Open: first published as 10.1136/bmjopen-2023-073425 on777Protected by copyright, including for7-87-87-87-8
13 14 15 16	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	7-8 7-8
17 18 19 20	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	7-8 7-8
21 22 23 24 25	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	as 10.1136/bmjopen-2023-073425 on 13 October 202:Protected by copyright, including for uses related to7-87-87-87-8
25 26 27	Methods: Monitoring			Eras Fralatec
28 29 30 31 32 33 34 35 36	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	7-8 n/a This trial sets two study mornitors (Page 8) instead of DMC. n/a
37 38 39 40 41	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a No interim analyses (Page 8)
42 43 44 45 46	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a No interim analyses, and similar technologies. 7 7 8
47 48 49 50 51	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	ay 21, 2025 at nologies. 7
52 53 54	Ethics and dissemination			t Departm
55 56 57 58	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	8 8
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	>

Page	19	of	19
rage	12	UI.	12

1 2 3 4 5 6	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	8
7 8 9	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
10 11 12 13 14	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
15 16 17 18	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	8
19 20 21 22	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	9
23 24 25 26 27	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
28 29 30	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	8
31 32 33 34 35 36 37 38	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	8
39 40 41	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	n/a
42 43 44 45 46	Dissemination policy: reproducible research Appendices	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
47 48	Informed consent	<u>#32</u>	Model consent form and other related documentation given to	Supplementary
49 50	materials		participants and authorised surrogates	materials
51 52 53 54 55 56 57 58	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-073425.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Jul-2023
Complete List of Authors:	liu, bin; Medical School of Chinese PLA; Chinese PLA General Hospital Xu, Junpeng; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yang, Haonan; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yu, Xinguang; Chinese PLA General Hospital, Department of Neurosurgery Mao, Zhiqi; Chinese PLA General Hospital, Department of Neurosurgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Neurology
Keywords:	Neurosurgery < SURGERY, Adult surgery < SURGERY, Adult neurology < NEUROLOGY



BMJ Open

Title: PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

(Revised Version 1.0, 2023.07.26)

Authors: Bin Liu^{1, 2†}, Junpeng Xu^{1, 2†}, Haonan Yang^{1, 2}, Xinguang Yu^{2, *}, Zhiqi Mao^{2, *}

Affiliation:

¹Medical School of Chinese PLA, Beijing, China

² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China

* Corresponding author:

Zhiqi Mao, MD, Department of Neurosurgery, the First Medical Center of Chinese PLA

General Hospital, Beijing, China, 100853

E-mail: markmaoqi@163.com

Xinguang Yu, MD, Department of Neurosurgery, the First Medical Center of Chinese

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PLA General Hospital, Beijing, China, 100853

E-mail: yuxinguang 301@163.com

[†] These authors have contributed equally to this work

ABSTRACT

Introduction Deep brain stimulation (DBS) has been validated as a safe and effective treatment for refractory cervical dystonia (CD). Globus pallidus internus (GPi) and subthalamic nucleus (STN) are the two main stimulating targets. However, there has been no prospective study to clarify which target is the better DBS candidate for CD. The objective of this trial is to compare directly the efficacy and safety of GPi-DBS and STN-DBS, thereby instructing the selection of DBS target in clinical practice.

Methods and analysis This multicenter, prospective, randomized, controlled study plans to enroll 98 refractory CD patients. Eligible CD patients will be randomly allocated to GPi-DBS group or STN-DBS group, with the DBS electrodes implanted into the posteroventral portion of GPi or the dorsolateral portion of STN, respectively. The primary outcome will be the improvement of symptomatic severity, measured by the changes in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity subscale and the Tsui scale at 3 months, 6 months, and 12 months after surgery. The secondary outcomes include the improvement of the TWSTRS-disability subscale, TWSTRS-pain subscale, quality of life, mental and cognitive condition, as well as the differences in stimulation parameters and adverse effects. In addition, this study intends to identify certain predictors of DBS efficacy for CD.

- Ethics and dissemination The trial has been approved by the Medical Ethics Committee of Chinese
- PLA General Hospital (S2022-613-01). The results of this study will be published in international
- peer-reviewed journals and shared in professional medical conferences.
- **Trial registration numbers** NCT05715138
- Key Words cervical dystonia, deep brain stimulation, globus pallidus internus, subthalamic nucleus.
- ARTICLE SUMMARY
- Strengths and limitations of this study
- The PASTS-CD study is the first randomized controlled study comparing the efficacy and safety of GPi-DBS and STN-DBS for cervical dystonia.
- The primary outcomes are evaluated blindly through randomly shuffled, de-identified, standardized videos to minimize potential biases.
- This trial uses the technique of imaging fusion to control the confounder of electrode position, which
 - is deemed to be the major influence factor of DBS efficacy.
 - One possible limitation is that investigators are not blinded because of the nature of the surgical intervention.
 - **INTRODUCTION**

Background and rationale

Cervical dystonia (CD), also known as spasmodic torticollis, is a type of focal dystonia, mainly manifesting as involuntary head turning or tilting, or holding a prolonged and twisted posture.^{1, 2} CD limits the neck activity by involving one or a group of neck muscles and is often accompanied

- by pain and psychological disorders, seriously compromising patients' life quality.²
- Medical treatment of CD is unsatisfactory. Oral medications are often ineffective or overshadowed by concomitant side effects.² Although most CD patients can be alleviated by injection of botulinum toxin, the remission is temporary so patients require multiple injections.³ Moreover, 25% of patients do not respond to botulinum toxin, and 20%-40% of patients discontinued botulinum toxin treatment due to lack of benefit.^{4, 5} Denervation and myotomy of the involved muscles is an effective surgery for CD once, but it becomes powerless in face of complicated cases.⁶

BMJ Open

Deep brain stimulation (DBS) has been substantiated to be a safe and effective therapy for primary CD, even for those medically refractory cases.⁷ The globus pallidus internus (GPi) was considered the preferred DBS target for various types of dystonia (including CD) with remarkable short-term and long-term efficacy.⁷⁻¹⁶ In addition, stimulation of the subthalamic nucleus (STN) has drawn increasing attention in recent years with the superiorities of lower stimulation parameters requirement and shorter onset time. A series of studies have demonstrated that STN-DBS is a promising alternative to GPi-DBS, with a long-term symptomatic improvement rate ranging from 50% to 90%,¹⁷⁻²¹ similar to and even higher than that of GPi-DBS. For studies focusing on CD only, both GPi-DBS^{10, 22-27} and STN-DBS^{17, 28, 29} show significant therapeutic effect. However, the question of which nucleus is the better DBS candidate for CD has not been clarified.

Previous comparisons of both targets were mainly about dystonia as a whole (including focal, segmental, and generalized dystonia). There was a prospective crossover study directly comparing the efficacy and safety of GPi-DBS and STN-DBS by implanting two sets of DBS electrodes for each dystonic patient and stimulating alternately one of them.^{30, 31} The results seemed to favor STN-DBS at the 6-month follow-up,³⁰ but no significant between-group difference was found at the over ten-years follow-up.31 Furthermore, another crossover study evaluated the effect of 24-hour stimulation of either STN or GPi for eight dystonic patients and also found no significant between-group difference.³² Retrospectively, STN-DBS was proven to outperform GPi-DBS in terms of movement improvement at the 1-month follow-up, but this superiority disappeared later, and at the 12-month follow-up, GPi-DBS was more efficient than STN-DBS in treatment of axial symptoms.³³ Moreover, another meta-regression analysis indicated that STN-DBS, relative to GPi-DBS, is associated with a better outcome in the univariate regression model but not in the multivariate model.³⁴ However, these studies did not distinguish specific phenotypes (not focus on CD). Additionally, the prospective studies were degraded by their small sample size and the retrospective analyses yielded inconsistent results.

For CD specifically, there have been no prospective studies to compare GPi-DBS with STN-DBS. From a retrospective perspective, a meta-analysis comparatively analyzed the results of 13 relative studies, including 58 CD patients undergoing GPi-DBS and 28 CD patients undergoing STN-DBS.³⁵ They found that when the factor of follow-up time was not taken into account, the improvement rates of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) subscores (severity, disability, and pain) were all significantly higher in the GPi-DBS group than that in the STN-DBS group, though the TWSTRS total score was not significantly different. Nevertheless, when the follow-up time was limited to three years, neither TWSTRS total score nor subscores showed a significantly between-group difference.³⁵ Similarly, another meta-analysis also failed to detect any significant difference — the improvement rates of the TWSTRS total score were 60.4% (GPi-DBS) and 56.6% (STN-DBS), respectively (p=0.936).³⁶ However, the two meta-analyses included low-quality studies and showed significant heterogeneity and publication bias. Surgeons still have confusion in the face of target selection before surgery. As such, a well-designed randomized controlled trial (RCT) is entailed to ascertain which one (STN or GPi) is the optimal DBS target for CD.

Objective

42 The PASTS-CD study aims to compare GPi-DBS with STN-DBS for drug-refractory CD in the
43 following aspects: (1) improvement of dystonic symptoms (severity, disability, and pain), (2)
44 improvement of life quality, mental status, and cognitive status, (3) stimulation parameters, (4)

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1		
2 3		
4	1	adverse effects. In the end, the study intends to identify the potential factors that are associated with
5	2	DBS efficacy in both groups.
6	3	METHODS AND ANALYSIS
7	4	Study design and setting
8 9	5	The PASTS-CD study is an investigator-initiated, multicenter, prospective, randomized, parallel-
10	6	controlled equivalence clinical trial, following the rules of Standard Protocol Items:
11	7	Recommendations for Interventional Trials (SPIRIT) guidelines. ³⁷ The method of minimization for
12	8	randomization will be used to produce two paralleling arms with an allocation ratio of 1:1, both of
13 14	9	which undergo the same procedures except for the difference in DBS target (GPi or STN). The flow
14	10	chart of the trial is presented in figure 1. This study will be implemented from September 1, 2023
16	11	to November 30, 2026 in four tertiary hospitals in China. This study only incorporates hospitals that
17		
18	12	have been qualified in DBS surgery for more than 5 years with more than 20 DBS operations per
19 20	13	year, and where DBS surgery-related complication rate is less than 5%. In addition, all investigators
21	14	will go through a standardized training before trial initiation.
22	15	Participants
23	16	Recruitment
24	17	The investigators will post the recruitment announcement on each center's official website and
25 26	18	WeChat account. CD Patients who are willing to participate in the trial will visit the dystonic
27	19	outpatient of each center.
28	20	Inclusion criteria
29	21	(1) Diagnosed as idiopathic or hereditary isolated CD;
30 31	22	(2) Severe functional impairment;
32	23	(3) Oral medication and injection of botulinum toxin become ineffective (> 3 months since last
33	24	injection), or refuse to adopt botulinum toxin injection;
34	25	(4) No secondary causes of CD;
35 36	26	(1) The secondary endses of CD;(5) Age 18-80 years old;
37	27	(6) Normal neurological examination except for dystonia;
38		
39	28	(7) Normal brain MRI;
40	29	(8) The subject or their family members can fully understand the trial and sign the informed
41 42	30	consent;
43	31	 consent; (9) Good compliance and willingness to receive regular follow-ups. <u>Exclusion criteria</u>
44	32	
45	33	(1) Diagnosed as secondary CD;
46 47	34	(2) CD with obvious trunk/limb involvement, or Meige syndrome;
47 48	35	(3) History of severe mental disorders, dementia, or epilepsy;
49	36	(4) Previous dystonia surgery (pallidotomy, thalamotomy, DBS, etc);
50	37	(5) Accompanied by other neurological diseases (Parkinson's disease, essential tremor, multiple
51	38	sclerosis, stroke, etc);
52 53	39	(6) The patient has or needs other implantable devices (cardiac pacemakers, defibrillators,
55	40	cochlear implants, spinal cord stimulators, etc.);
55	41	(7) Pregnant women or women who are waiting to become pregnant during the trial;
56	42	(7) Tregnant women of women who are waiting to become pregnant during the triar,(8) Poor health condition.
57 59		
58 59	43	Dropout or suspension of the trial (1) Poston particle infection that requires removal of DBS electrodes:
60	44	(1) Postoperative infection that requires removal of DBS electrodes;
		2 / 12

1 (2) Severe displacement of DBS electrodes position from the predefined targets (> 3mm for STN-

- 2 DBS group and > 5mm for GPi-DBS group);
 - 3 (3) Occurrence of severe adverse events or other serious diseases that interfere with the efficacy
- 4 assessment;
 - 5 (4) Loss to follow up;
 - 6 (5) Requests from patients to withdraw from the trial;
- 7 Interventions
- 8 <u>Baseline evaluation</u>

For each eligible patient, the basic information, medical history, disease characteristics, and medications will be recorded in the electronic medical record system in detail. Besides, physical examination, routine blood tests, and MRI scanning are assigned before surgery. Every patient will be videotaped as per a standardized scheme (see supplementary material) at least one day after drug withdrawal. These videos will be collected and transferred to two neurological raters who will complete the TWSTRS-severity subscale and Tsui scale blindly and separately at the end of the trial. Moreover, the TWSTRS-disability subscale, TWSTRS-pain subscale, 36-item Short Form General Health Survey (SF-36), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) will also be completed before surgery. The timeline of data collection is shown in table 1. After signature of the informed consent form, candidate patients will be randomized into the GPi-DBS group or the STN-DBS group.

21 DBS surgery

Certain minor differences in surgical procedures are allowed among involved centers as long as the electrodes are placed safely and accurately, but some critical steps must keep in line with each other. Specifically, on the day of surgery, a stereotactic head frame is fixed on the patient's head, followed by a CT scan. The frame CT images and the preoperative MRI images $(1.0 * 1.0 * 1.0 mm^3, no gap)$ will be fused in a surgical planning system, where the coordinates of the targets and trajectories are determined. DBS electrodes are implanted with the assistance of a stereotactic frame or neurosurgical robot under general anesthesia with bi-spectral index monitoring (BIS). After completion of burr holes, microelectrode recording (MER) is monitored intraoperatively to further assist the targeting of nuclei. The dosage of propofol should be reduced on recording, keeping the value of BIS fluctuating around 70, so as not to affect neuronal discharges.³⁸ An eligible firing pattern should be recorded as described by Robert, et al.³⁹ If not, the target should be adjusted or use two- or multiple-channel recording. Passive limb movements can be helpful to identify the sensorimotor subregion of the nuclei. Given that patients are under general anesthesia and their heads are immobilized by the frame, intraoperative macrostimulation can be omitted. Subsequently, according to the randomized allocation, the corresponding quadripolar electrodes will be implanted into posteroventral GPi (GPi-DBS group) or dorsolateral STN (STN-DBS group), bilaterally. The implanted electrodes can be selected from anyone of the following three manufacturers: Medtronic (Minneapolis, USA), PINS Medical (Beijing, China), and SceneRay (Suzhou, China). Of note, in light of the volume difference between the two nuclei, electrodes with contact intervals of 1.5mm are chosen for GPi-DBS, but 0.5mm for STN-DBS. Afterwards, inserted leads will be fixed at the burr hole site and an implantable pulse generator (IPG) will be connected and implanted at the right subclavicular area subcutaneously.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

5944Electrode position confirmation60

If possible, an intraoperative MRI scanning is strongly recommended to verify the implantation accuracy. Otherwise, a postoperative MRI or CT scanning is compulsory before discharge from hospitals. In order to exclude the effect of electrode position on the DBS efficacy, the intraopetative or postoperative images are fused with the preoperative images. If the deviating Euclidean distance between the lead tip and the predefined target exceeds 3mm (STN-DBS group) or 5mm (GPi-DBS

group), the subject will be dropped out.

Follow-up

One month later, the DSB will be activated by a specialized DBS programmer in the outpatient department. To evaluate stimulation effects and adverse effects of both electrodes, all contacts will be screened in a monopolar mode with the voltage increasing gradually from 1V to 4V and pulse width and frequency kept at 60us and 130Hz. For those whose symptoms improve rapidly, the optimal parameters will be documented and used for chronic stimulation. For those who lack an acute improvement, the activated contact is identified based on the results of MER or the 3D reconstruction of the electrodes via the Lead DBS software (the contact closest to the posteroventral GPi or the dorsolateral STN), and the voltage is set at 25% below the threshold for causing a stimulation-related adverse effect. At the 3-month follow-up, a standardized video will be recorded and TWSTRS-disability and pain subscales are completed by a centrally-trained rater. At the 6-month and 12-month follow-ups, in addition to the standardized video and TWSTRS subscales, all the other scales (i.e. SF-36, HAMA, HAMD, MMSE, and MoCA) will also be evaluated (table 1). Of note, to focus on the effect of DBS and exclude the confounding effect of medication, botulinum toxin injection is forbidden during the follow-up period, and the patient should stop taking oral medication for one day before each evaluation. Furthermore, throughout the implementation of the trial, all adverse effects must be handled in safety and documented in detail, regardless of surgery-derived, device-related, or stimulation-induced events. Regular programming will also be performed at each follow-up to find the best parameters. The initial stimulating setting can be modulated at any time when the patients feel unsatisfactory about the symptom control or encounter a stimulation-induced adverse effect.

Outcome measurements

The primary outcomes are the changes (improvement rates) of the TWSTRS-severity subscale and the Tsui scale at 3 months, 6 months, and 12 months after surgery. The reason why these two scales are chosen as the primary outcomes is that both of them are obtained from standardized videos, while the TWSTRS disability and pain subscales can be acquired via questionnaires. The Tsui scale is a rational complement to the TWSTRS-severity subscale by adding the assessment of head tremor. The secondary outcomes are the changes (improvement rates) of the TWSTRS-disability subscale, TWSTRS-pain subscale, the difference of stimulation parameters and adverse effects at 3 months, 6 months, and 12 months after surgery, as well as the SF-36 questionnaire, HAMA scale, HAMD scale, MMSE scale, and MoCA scale at 6 months and 12 months after surgery. The improvement rate of each scale can be calculated by the following formula: (score at each follow-up time point -baseline score) / baseline score *100%. Stimulation parameters are mirrored by the total electrical energy delivered (TEED = voltage² * pulse width * frequency *1 second / impedance).⁴⁰ The higher the TEED, the shorter the battery life of the stimulator.

Table 1 Participant timeline of data collection.

57	42	Table I Participant timeline of data collection.
58		Enrolme Allocatio Post- Follow-up
59		nt n/Surgery Surger
60		у
		5 / 12

BMJ Open

2									
3		TIMEPOINT	-1	0	1	4	12	24	48
4		(weeks±1)							(Close-out)
5 6		ENROLMENT :							
7		Eligibility screen	Х						
8		Informed consent	х						
9 10		Medical history	х						
11		MRI scanning	Х		Х				
12		Allocation		Х					
13 14		INTERVENTIONS :							
14		GPi-DBS surgery		Х					
16		STN-DBS surgery		Х					
17		DBS				Х	Х	Х	Х
18 19		ASSESSMENTS :							
20		Standardized video*	Х				Х	Х	Х
21		TWSTRS-disability	X				Х	Х	Х
22 23		TWSTRS-pain	X				Х	х	Х
23 24		SF-36	x					х	Х
25		HAMA	x					х	Х
26		HAMD	x					х	Х
27 28		MMSE	х					х	Х
<u>10</u> 29		MoCA	Х					х	Х
30		Medication	х				х	Х	Х
31		Stimulation				х	X	X	X
32 33		parameters							
34		Adverse effects		Х	х	x	х	Х	Х
35		* For assessment of TWSTR	S-severity :						
36 37	1	Sample size				4			
38	2	The sample size is calculate	d based	on one of	f the prin	nary outc	omes —	the impr	ovement rate
39	3	TWSTRS-severity subscore.			-	2		-	
40 41	4	DBS with STN-DBS for CD		-				•	
12	5	at the same follow-up time			-				-
43	6	respectively. ³⁵ Based on the r	· •	,					
44 4 F	7	required to reach a significar			•	-			U 1
45 46	, 8	patients would be withdrawn					-		-
47	9	up, a total of 98 CD patients					-	s would t	
18		1, 1		neu (49 p	atients to	or each gr	oup).		
19 :0	10	Randomization and blindin	0	1) () CD		TD		1	• 1
50 51	11 12	Patients will be randomly ass	•	-	•	-	-		• •
52	12	web-based randomization s							
53	13	component with gender (mathematical (≤ 2 areas ≥ 2 and				-			
54 55	14	duration (< 3 years or \geq 3 ye				-			
56	15	by participating centers. A s	-	-					
57	16	surgery submits the basic inf							
58	17	code and grouping informati	on will l	be returne	d automa	atically. (Only this	neurosur	geon has acce
.u	40								

59 18 to the central randomization system.60

Investigators (neurosurgeons) are not blinded because of the nature of the surgical intervention, but patients, scale raters, and data analysts are blinded. At the time of scale scoring and video recording, each patient wears an operating cap so that scale raters are blinded to the condition of surgery (preoperatively or postoperatively). All standardized videos recorded for evaluation of the TWSTRS-severity subscale and the Tsui scale will be shuffled randomly and scored twice centrally by two experienced neurologists who do not know the grouping information and time points of follow-up. The mean score values of the two neurologists will be documented and uploaded. Furthermore, before data is transferred to data analysts for statistical analysis, the data manager will mask the grouping information and set two groups as A and B instead. Only when the subjects are withdrawn would they be unblinded.

11 Data collection and management

The schematic chart for data collection is shown in table 1. Prior to the enrollment of the first patient, all investigators (including neurosurgeons, coordinators, scale raters, DBS programmers, data managers, etc) have to receive standardized training in data collection and management. At baseline and each follow-up time point, all information (medical history, scales, videos, programming parameters, and adverse effects) will be transferred to a coordinator who will then fill in the case report forms (CRFs). All items in CRFs have to be completed and any correction should be noted and explained. Eventually, two coordinators upload the standardized videos and input the information of CRFs into the electronic data capture (EDC) system — Whole Course Management Service Platform (https://admin.demo.sdc.sinohealth.com/login).

- Notably, the EDC system is linked with a patient client that can be installed on patients' or their family's mobile phones, through which, investigators can push disease-related knowledge or questionnaires (for example, SF-36) to patients and conversely, patients can submit questionnaires and express their complaints to investigators at any time. Before each follow-up time point, patients will receive an alert from this client, thereby improving follow-up compliance.
- During data collection, two data monitors will audit the contents of the CRFs to ensure data authenticity and accuracy. In addition, a data manager will review the EDC data online in real-time and check the data consistency. Any data error or query existing, the data manager will send it back to the corresponding center where the investigators will check the original documents, answer the query, and update the data. At the end of the trial, the data manager will lock the EDC database and send the data to two data analysts for analysis.
- All data files should be managed with great care and confidentiality. Only authorized investigators
 All data files should be managed with great care and confidentiality. Only authorized investigators
 can login the EDC system with a password and any modification trace on the DEC platform will be
 preserved. Additionally, all original scale files and CRFs will be locked in a special cabinet and all
 video files will be stored in an encrypted folder.

36 Data monitor

- Any adverse events during the study period should be documented in detail, including the
 information of event date, category, severity, treatment, and prognosis. If severe adverse events
 occur, the principal investigator must be notified within 24 hours.
- 40 Two study monitors who are independent of the implementation of this trial and have no competing
 41 interests will regularly visit the participating centers to inspect the protocol adherence, recruitment
 42 status, data collection, reporting of adverse events, and subject dropout rate. The monitoring results
 43 will be presented to the principal investigator and the local ethics committee. The interim analyses

 Page 9 of 20

1 are unnecessary because plenty of previous studies have confirmed the safety of DBS surgery of

2 both targets.^{7, 10, 14, 16, 17, 29} Herein, this trial only concentrates on their potential differences.

3 Statistical analysis

Outcome statistics will be performed using cases with complete data, i.e., per protocol (PP) analyses. In addition, for the primary outcomes, an intention-to-treat (ITT) analysis (including all patients assigned in the trial) will also be performed with missing values imputed by multiple interpolations. Continuous variables will be presented as means \pm standard deviations for normally distributed data or as medians (interquartile ranges) for skewed data. Categorical variables will be presented as frequencies or percentages. For difference analyses of baseline information, this study uses the Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. Moreover, two-way ANOVA will be used to analyze the main effects (group or time) and the interaction effects. Within-group post hoc comparisons between different time points will be analyzed by paired T test or Wilcoxon signed-rank sum tests. Between-group comparisons at a certain time point will be analyzed using the Wilcoxon rank-sum test. Factors associated with DBS efficacy, such as gender, age at surgery, and disease duration, will be included as covariates.^{31, 34, 41} Of note, when analyzing the adverse effects, those patients who have been withdrawn due to severe adverse effects should be included. Finally, to explore predictors of DBS outcomes, this study uses simple linear regression first to screen variables relevant to the improvement rates of TWSTRS, and multiple linear regression second to identify independent variables.

- 21 A difference of p < 0.05 (two-tailed) is specified as statistically significant. SPSS 26 statistical
- software will be used for statistical analyses.

23 ETHICS AND DISSEMINATION

The PASTS-CD trial protocol has been approved by the Medical Ethics Committee of Chinese PLA
General Hospital (S2022-613-01), which is also responsible for re-examining protocol
modifications in the future, if any. Moreover, this trial has been registered on Clinicaltrials.gov
(NCT05715138).

The investigators have to explain the objectives of this trial and every surgical detail to the patients or their families, and the informed consent form must be signed before allocation. For those patients with surgical sequelae, this study provides ancillary and post-trial care according to standard medical practice.

The investigators have access to the final results, which will be published in international peerThe investigators have access to the final results, which will be published in international peerreviewed journals and shared in professional medical conferences. The raw data can be available
from the corresponding author upon reasonable request. Patients' information will be de-identified
and videos will be mosaicked before exhibition.

36 DISCUSSION

- 5037To the best of our knowledge, the PASTS-CD study is the first prospective RCT study directly5138comparing the efficacy and safety of GPi-DBS and STN-DBS for refractory CD patients. The results5239of this trial will be a powerful guide for neurosurgeons in the selection of DBS targets for CD5440patients.
- One notable advantage of this trial is that the primary outcomes are quantified by standardized videos centrally and blindly by two neurologists. The customized scheme of standardized video recording has been tested to suffice for the scoring of the TWSTRS-severity subscale and Tsui scale.
- 59 44 This design will eliminate the measurement bias from different scale raters of different centers and 60

the interviewer bias from the subjectivity of scale raters. Another advantage is that this trial controls the confounding effect of electrode implantation accuracy, which is considered to be the most relevant factor to DBS efficacy.^{42, 43} Due to the small size of the subcortical nuclei and the complex surrounding structures, a minor deviation from the target will bring about a significant disparity in DBS efficacy and adverse effects. Through measuring the distance between the sensorimotor subregion of target nuclei and the contacts of electrodes, the investigators exclude those subjects in which the volume of tissue activated (VTA) of DBS electrodes is speculated to show no or a low overlapping with the sensorimotor subregion of target nuclei. According to previous experiences^{44,} ⁴⁵ and the volume difference between the two targets, the cutoff distance is defined to be 3mm for the STN-DBS group and 5mm for the GPi-DBS group. This procedure also minimizes the influence of technical discrepancy of different neurosurgeons.

One possible limitation is that the neurosurgeons are not blinded, but this is determined by the nature of the surgical intervention. In fact, the main role of neurosurgeons is implanting the DBS electrodes into the predefined subregion of the two subcortical nuclei, and they do not participate in the subsequent scales scoring and DBS programming. As such, by controlling the accuracy of electrode position, the accompanying bias from the unblinded neurosurgeons will be significantly reduced. In addition, owing to the low incidence of CD, the investigators have to initiate a multicenter study to meet the requirement of sample size. Although multicenter studies may increase heterogeneity to some extent, it is believed that strict protocol implementation, coupled with systematic training and constant study monitoring, will help to minimize the biases and maximize the reliability of results.

- 22 Author affiliations
- 23 ¹ Medical School of Chinese PLA, Beijing, China
- ² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing,
 - 25 China

- 26 Acknowledgements None
- 27 Contributors
- Study conception: MZQ and YXG. Initial study design: LB and XJP. Revision of study design and
 protocol: MZQ. statistical analysis: YHN. Study coordination: YXG. Drafting the manuscript: LB
- 30 and XJP. All authors read and approved the final manuscript.
- **31 Funding** This trial is supported by STI 2030 Major Projects (2021ZD0200407).
- **Competing interests** None declared.
- 33 Patients and public involvement Patients and the public are not involved in the design and34 implementation of this trial.
- 495035 Patient consent for publication Not applicable.
- 51 36 **Provenance and peer review** Not commissioned; externally peer-reviewed.
- 52 37 Data availability statement Data are available upon reasonable request.
- 53 38 ORCID iD
- 39
 Bin Liu http://orcid.org/0000-0001-5114-7350
- 56 40
- 50 42 60 43

9 / 12

References

Page 11 of 20


BMJ Open


2		
l		
l		
	Pr	
l	otecte	
	d by cc	
	opyrigh	
L	ıt, incl	
•	uding t	
l	for use	
,	Era s relat	
	ed to t	
	Erasmushogeschoo elated to text and da	
	l data r	
L	nining,	
	Al tra	
	ining, a	
l	and sin	
	Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	
,	chnok	
l	ogies.	

1. Albanese A. Deep brain stimulation for cervical dystonia. Lancet Neurol 2014;13:856-7. 2. Crowner BE. Cervical dystonia: disease profile and clinical management. Phys Ther 2007;87:1511-26. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of 3. cervical dystonia. Drugs 2002;62:705-22. 4. Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol 2015;262:837-48. 5. Jinnah HA, Comella CL, Perlmutter J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 2018;147:89-95. 6. Ravindran K, Ganesh Kumar N, Englot DJ, Wilson TJ, Zuckerman SL. Deep Brain Stimulation Versus Peripheral Denervation for Cervical Dystonia: A Systematic Review and Meta-Analysis. World Neurosurg 2019;122:e940-e46. Rodrigues FB, Duarte GS, Prescott D, Ferreira J, Costa J. Deep brain stimulation for dystonia. 7. Cochrane Database Syst Rev 2019;1:CD012405. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in 8. primary generalized dystonia. N Engl J Med 2005;352:459-67. 9. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-90. 10. Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457-9. 11. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007;6:223-9. 12. Mueller J, Skogseid IM, Benecke R, et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord 2008;23:131-4. 13. Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;11:1029-38. 14. Moro E, LeReun C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. Eur J Neurol 2017;24:552-60. 15. Meoni S, Fraix V, Castrioto A, et al. Pallidal deep brain stimulation for dystonia: a long term study. J Neurol Neurosurg Psychiatry 2017;88:960-67. 16. Krause P, Volzmann S, Ewert S, et al. Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years. J Neurol 2020;267:1622-31. 17. Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011;76:870-8. 18. Zhan S, Sun F, Pan Y, et al. Bilateral deep brain stimulation of the subthalamic nucleus in primary Meige syndrome. J Neurosurg 2018;128:897-902. 19. Ostrem JL, San Luciano M, Dodenhoff KA, et al. Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. Neurology 2017;88:25-35. 20. Deng Z, Pan Y, Zhang C, et al. Subthalamic deep brain stimulation in patients with primary dystonia: A ten-year follow-up study. Parkinsonism Relat Disord 2018;55:103-10. 21. Cao C, Pan Y, Li D, et al. Subthalamus deep brain stimulation for primary dystonia patients: a long-term follow-up study. Mov Disord 2013;28:1877-82.

3		
4	1	22. Chung M, Huh R. Different clinical course of pallidal deep brain stimulation for phasic- and tonic-
5	2	type cervical dystonia. Acta Neurochir (Wien) 2016;158:171-80; discussion 80.
6	3	23. Kaelin-Lang A, You H, Burgunder JM, et al. Bilateral pallidal stimulation improves cervical
7	4	dystonia for more than a decade. Parkinsonism Relat Disord 2020;81:78-81.
8 9	5	24. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-
10	6	refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014;13:875-84.
11	7	25. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain
12	8	stimulation for cervical dystonia. Brain 2007;130:2879-86.
13	9	26. Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia:
14 15	10	blinded evidence of benefit beyond 5 years. Brain 2013;136:761-9.
16		
17	11	27. Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation
18	12	in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 2012;19:610-5.
19	13	28. Yin F, Zhao M, Yan X, et al. Bilateral subthalamic nucleus deep brain stimulation for refractory
20 21	14	isolated cervical dystonia. Sci Rep 2022;12:7678.
22	15	29. Gupta A. Subthalamic stimulation for cervical dystonia. Acta Neurochir (Wien) 2020;162:1879-81.
23	16	30. Schjerling L, Hjermind LE, Jespersen B, et al. A randomized double-blind crossover trial comparing
24	17	subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg 2013;119:1537-45.
25	18	31. Hock AN, Jensen SR, Svaerke KW, et al. A randomised double-blind controlled study of Deep
26 27	19	Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 years. Parkinsonism
28	20	Relat Disord 2022;96:74-79.
29	21	 Liu Y, Zhu G, Jiang Y, et al. Comparison of Short-Term Stimulation of the Globus Pallidus Interna
30		
31	22	and Subthalamic Nucleus for Treatment of Primary Dystonia. World Neurosurg 2019;123:e211-e17.
32	23	33. Lin S, Wu Y, Li H, et al. Deep brain stimulation of the globus pallidus internus versus the
33 34	24	subthalamic nucleus in isolated dystonia. J Neurosurg 2019;132:721-32.
35	25	34. Wu YS, Ni LH, Fan RM, Yao MY. Meta-Regression Analysis of the Long-Term Effects of Pallidal
36	26	and Subthalamic Deep Brain Stimulation for the Treatment of Isolated Dystonia. World Neurosurg
37	27	2019;129:e409-e16.
38	28	35. Hua X, Zhang B, Zheng Z, et al. Predictive factors of outcome in cervical dystonia following deep
39 40	29	brain stimulation: an individual patient data meta-analysis. J Neurol 2020;267:1780-92.
41	30	36. Tsuboi T, Wong JK, Almeida L, et al. A pooled meta-analysis of GPi and STN deep brain
42	31	stimulation outcomes for cervical dystonia. J Neurol 2020;267:1278-90.
43	32	37. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
44	33	
45 46		protocols of clinical trials. BMJ 2013;346:e7586.
47	34	38. Venkatraghavan L, Rakhman E, Krishna V, et al. The Effect of General Anesthesia on the
48	35	Microelectrode Recordings From Pallidal Neurons in Patients With Dystonia. J Neurosurg Anesthesiol
49	36	2016;28:256-61.
50	37	39. Gross RE, Krack P, Rodriguez-Oroz MC, Rezai AR, Benabid AL. Electrophysiological mapping
51 52	38	for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord 2006;21
53	39	Suppl 14:S259-83.
54	40	40. Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by deep
55	41	brain stimulation systems. Ann Neurol 2005;58:168; author reply 68-9.
56	42	41. Isaias IU, Volkmann J, Kupsch A, et al. Factors predicting protracted improvement after pallidal
57 58	43	DBS for primary dystonia: the role of age and disease duration. J Neurol 2011;258:1469-76.
50 59		
60	44	42. Wodarg F, Herzog J, Reese R, et al. Stimulation site within the MRI-defined STN predicts

1		
2		
3	1	postoperative motor outcome. Mov Disord 2012;27:874-9.
4	2	43. Park HR, Lee JM, Ehm G, et al. Correlation of electrode position and clinical outcomes in globus
5 6	3	pallidus stimulation for dystonia. Acta Neurochir (Wien) 2017;159:1349-55.
7		
8	4	44. Zhang D, Lin H, Liu J, et al. Electrode Reconstruction Assists Postoperative Contact Selection in
9	5	Deep Brain Stimulation. World Neurosurg 2019;125:e442-e47.
10	6	45. Astrom M, Diczfalusy E, Martens H, Wardell K. Relationship between neural activation and electric
11 12	7	field distribution during deep brain stimulation. IEEE Trans Biomed Eng 2015;62:664-72.
12	8	
14	9	
15	10	Figure legend
16	11	
17	12	Figure 1 Flow chart of the PASTS-CD study. GPi, globus pallidus internus; STN, subthalamic nucleus; DBS, deep brain stimulation.
18 19	13	nucleus, 225, deep oran binnanation.
20	10	
21	14	
22		
23		
24 25		
26		
27		
28		
29		
30 31		
32		
33		
34		
35		
36 37		
38		
39		
40		
41		
42 43		
43 44		
45		
46		
47		
48 49		
49 50		
51		
52		
53		
54 55		
55 56		
57		
58		
59		
60		12 / 12
		12/12





529x651mm (72 x 72 DPI)

Checklist

#1 #2a #2b #3 #4 #5a	Reporting Item Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier Sources and types of financial, material, and other support	Page Num Title Page 1, 8 n/a Title Page
<u>#2a</u> <u>#2b</u> <u>#3</u> <u>#4</u>	interventions, and, if applicable, trial acronym Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier	1, 8 n/a Title Page
<u>#2a</u> <u>#2b</u> <u>#3</u> <u>#4</u>	interventions, and, if applicable, trial acronym Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier	1, 8 n/a Title Page
<u>#2b</u> <u>#3</u> <u>#4</u>	intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier	n/a Title Page
<u>#3</u> <u>#4</u>	Data Set Date and version identifier	Title Page
<u>#4</u>		Ū.
	Sources and types of financial, material, and other support	
#5a		9
	Names, affiliations, and roles of protocol contributors	Title Page, 9
<u>#5b</u>	Name and contact information for the trial sponsor	n/a (no sponsor)
<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a (no sponsor)
<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a
<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	1-2
	<u>*5d</u>	 collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	1
5 6 7	Objectives	<u>#7</u>	Specific objectives or hypotheses	2-3
7 8 9 10 11 12 13	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	3
14	Methods:			
15	Participants,			
16 17	interventions, and			
18	outcomes			
19 20 21 22 23	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	3
24 25 26 27 28	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	3
29 30 31	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	4-5
32 33 34 35 36	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	4
37 38 39 40 41	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7
42 43 44	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	5
45 46 47 48 49 50 51 52 53	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	5
54 55 56 57 58	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-6
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
5 6 7 8	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	3
9 10 11 12 13 14	Methods: Assignment of interventions (for controlled trials)			
15 16 17 18 19 20 21 22	Allocation: sequence generation	<u>#16a</u>	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6
23 24 25 26 27 28 29	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6
30 31 32	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6
33 34 35 36 37	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7
38 39 40 41 42	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	7
43	Methods: Data			
44 45	collection,			
46 47 48	management, and analysis			
49 50 51 52 53 54 55 56 57 58	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6, 6-7
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7
5 6 7 8 9 10 11 12	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7
12 13 14 15 16 17	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	8
17 18 19 20	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	8
21 22 23 24 25	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	8
26 27	Methods: Monitoring			
28 29	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of	n/a
30 31	formal committee		its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and	This trial sets
32 33			reference to where further details about its charter can be found,	two study morni
34 35 36			if not in the protocol. Alternatively, an explanation of why a DMC is not needed	(Page 7-8) inste of DMC.
37 38	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping guidelines,	n/a
39 40	interim analysis		including who will have access to these interim results and make the final decision to terminate the trial	No interim analy
41 42				(Page 7-8)
43 44 45 46	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	7
47 48 49 50 51	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	7
52 53 54	Ethics and dissemination			
55 56 57 58	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	8
59 60		For peer	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page	19	of	20
ruge		01	20

1 2 3 4 5 6	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	8
7 8 9	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
10 11 12 13 14	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
15 16 17 18	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	8
19 20 21 22	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	9
23 24 25 26 27	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
28 29 30	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	8
31 32 33 34 35 36 37 28	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	8
38 39 40 41	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	n/a
42 43 44 45	Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
46 47	Appendices			
48 49	Informed consent	<u>#32</u>	Model consent form and other related documentation given to	Supplementary
50 51	materials		participants and authorised surrogates	materials
52 53 54 55 56 57 58	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1

Scheme of Standardized Video Recording

1. Seated position. (The patient wears a surgical cap with head, neck and shoulders on camera.) ① Eyes closed (20 seconds: 10 seconds recorded from the front and 10 seconds from the side). Say to the patient, "Please sit down, close your eyes, and put your head where you feel most comfortable." ② Eyes open (10 seconds: 5 seconds recorded from the front and 5 seconds from the side). Say to the patient, "Please sit down, open your eyes, and try to look straight ahead and keep your head in the middle." ③ Turn head right and turn head left (5 seconds each) Say to the patient: "Look forward to the camera, turn your head to the right as far as you can, and then turn your head to the left as far as you can." ④ Head up and head down (5 seconds each) Say to the patient: "Look forward to the camera, raise your head as high as you can, and then lower your head as low as you can." ⑤ Put the ear close to the right shoulder and then the left shoulder (5 seconds each). Say to the patient, "Look forward to the camera. Now bring your right ear as close to your right shoulder as possible, and do not move your right shoulder." Say to the patient, "Look forward to the camera. Now bring your left ear as close to your left shoulder as possible, and do not move your left shoulder." ⁽⁶⁾ Symptom persistence Ask the patient, "If you divide your awake time during the day into four equal parts, how many parts do neck abnormalities take up?" (7) Symptom characteristics Ask the patient, "Does each episode come on suddenly or gradually?" (8) Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds) Say to the patient, "Please try to put your head in a straight position and look forward to the camera for one minute. Now start the clock." (9) Rest (10 seconds) Say to the patient, "Rest for 10 seconds." (1) Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds) Say to the patient, "Please do it again. Try to put your head in a straight position and look forward to the camera for one minute. Now start the clock." (11) Sensory tricks Say to the patient, "Are there some movements or postures you can do to straighten your head? If so, try to do it." 2. Standing position (Show the whole body) (1) Anterior view (5 seconds) Say to the patient, "Please stand up and face the camera." 2 Lateral view (5 seconds) Say to the patient, "Please turn 90 degrees to the left (or right)." 3. Walking (10 seconds) Say to the patient, "Please walk forward to the door and turn back."

PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-073425.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Aug-2023
Complete List of Authors:	liu, bin; Medical School of Chinese PLA; Chinese PLA General Hospital Xu, Junpeng; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yang, Haonan; Medical School of Chinese PLA; Chinese PLA General Hospital, Department of Neurosurgery Yu, Xinguang; Chinese PLA General Hospital, Department of Neurosurgery Mao, Zhiqi; Chinese PLA General Hospital, Department of Neurosurgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Neurology
Keywords:	Neurosurgery < SURGERY, Adult surgery < SURGERY, Adult neurology < NEUROLOGY



BMJ Open

h	
2	
3	
4	
-	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
16 17	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
20	
57	
58	

59 60 Title: PAllidal versus SubThalamic deep brain Stimulation for Cervical Dystonia (PASTS-CD): study protocol for a multicenter randomized controlled trial

(Revised Version 3.0, 2023.08.22)

Authors: Bin Liu^{1, 2†}, Junpeng Xu^{1, 2†}, Haonan Yang^{1, 2}, Xinguang Yu^{2, *}, Zhiqi Mao^{2, *}

Affiliation:

¹ Medical School of Chinese PLA, Beijing, China

² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China

* Corresponding author:

Zhiqi Mao, MD, Department of Neurosurgery, the First Medical Center of Chinese PLA

General Hospital, Beijing, China, 100853

E-mail: markmaoqi@163.com

Xinguang Yu, MD, Department of Neurosurgery, the First Medical Center of Chinese

PLA General Hospital, Beijing, China, 100853

E-mail: yuxinguang_301@163.com

† These authors have contributed equally to this work

1 ABSTRACT

Introduction Deep brain stimulation (DBS) has been validated as a safe and effective treatment for
refractory cervical dystonia (CD). Globus pallidus internus (GPi) and subthalamic nucleus (STN) are
the two main stimulating targets. However, there has been no prospective study to clarify which target
is the better DBS candidate for CD. The objective of this trial is to compare directly the efficacy and
safety of GPi-DBS and STN-DBS, thereby instructing the selection of DBS target in clinical practice.

Methods and analysis This multicenter, prospective, randomized, controlled study plans to enroll 98 refractory CD patients. Eligible CD patients will be randomly allocated to GPi-DBS group or STN-DBS group, with the DBS electrodes implanted into the posteroventral portion of GPi or the dorsolateral portion of STN, respectively. The primary outcome will be the improvement of symptomatic severity, measured by the changes in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity subscale and the Tsui scale at 3 months, 6 months, and 12 months after surgery. The secondary outcomes include the improvement of the TWSTRS-disability subscale, TWSTRS-pain subscale, quality of life, mental and cognitive condition, as well as the differences in stimulation parameters and adverse effects. In addition, this study intends to identify certain predictors of DBS efficacy for CD.

Ethics and dissemination The trial has been approved by the Medical Ethics Committee of Chinese
PLA General Hospital (S2022-613-01). The results of this study will be published in international peerreviewed journals and shared in professional medical conferences.

- **19 Trial registration numbers** NCT05715138
- 20 Key Words cervical dystonia, deep brain stimulation, globus pallidus internus, subthalamic nucleus.

21 ARTICLE SUMMARY

- 22 Strengths and limitations of this study
- The PASTS-CD study is the first randomized controlled study comparing the efficacy and safety of
 GPi-DBS and STN-DBS for cervical dystonia.
- The primary outcomes are evaluated blindly through randomly shuffled, de-identified, standardizedvideos to minimize potential biases.
- This trial uses the technique of imaging fusion to control the confounder of electrode position, which is
 - deemed to be the major influence factor of DBS efficacy.
 - One possible limitation is that investigators are not blinded because of the nature of the surgicalintervention.

31 INTRODUCTION

32 Background and rationale

4533Cervical dystonia (CD), also known as spasmodic torticollis, is a type of focal dystonia, mainly4634manifesting as involuntary head turning or tilting, or holding a prolonged and twisted posture.[1, 2] CD4735limits the neck activity by involving one or a group of neck muscles and is often accompanied by pain4936and psychological disorders, seriously compromising patients' life quality.[2]

Medical treatment of CD is unsatisfactory. Oral medications are often ineffective or overshadowed by concomitant side effects.[2] Although most CD patients can be alleviated by injection of botulinum toxin, the remission is temporary so patients require multiple injections.[3] Moreover, 25% of patients do not respond to botulinum toxin, and 20%-40% of patients discontinued botulinum toxin treatment due to lack of benefit.[4, 5] Denervation and myotomy of the involved muscles is an effective surgery

1 / 12

Page 3 of 21

BMJ Open

for CD once, but it becomes powerless in face of complicated cases.[6] Deep brain stimulation (DBS) has been substantiated to be a safe and effective therapy for primary CD, even for those medically refractory cases.[7] The globus pallidus internus (GPi) was considered the preferred DBS target for various types of dystonia (including CD) with remarkable short-term and long-term efficacy.[7-16] In addition, stimulation of the subthalamic nucleus (STN) has drawn increasing attention in recent years with the superiorities of lower stimulation parameters requirement and shorter onset time. A series of studies have demonstrated that STN-DBS is a promising alternative to GPi-DBS, with a long-term symptomatic improvement rate ranging from 50% to 90% [17-21] similar to and even higher than that of GPi-DBS. For studies focusing on CD only, both GPi-DBS[10, 22-27] and STN-DBS[17, 28, 29] show significant therapeutic effect. However, the question of which nucleus is the better DBS candidate for CD has not been clarified. Previous comparisons of both targets were mainly about dystonia as a whole (including focal, segmental,

and generalized dystonia). There was a prospective crossover study directly comparing the efficacy and safety of GPi-DBS and STN-DBS by implanting two sets of DBS electrodes for each dystonic patient and stimulating alternately one of them. [30, 31] The results seemed to favor STN-DBS at the 6-month follow-up,[30] but no significant between-group difference was found at the over ten-years follow-up.[31] Furthermore, another crossover study evaluated the effect of 24-hour stimulation of either STN or GPi for eight dystonic patients and also found no significant between-group difference.[32] Retrospectively, STN-DBS was proven to outperform GPi-DBS in terms of movement improvement at the 1-month follow-up, but this superiority disappeared later, and at the 12-month follow-up, GPi-DBS was more efficient than STN-DBS in treatment of axial symptoms.[33] Moreover, another meta-regression analysis indicated that STN-DBS, relative to GPi-DBS, is associated with a better outcome in the univariate regression model but not in the multivariate model.[34] However, these studies did not distinguish specific phenotypes (not focus on CD). Additionally, the prospective studies were degraded by their small sample size and the retrospective analyses yielded inconsistent results.

For CD specifically, there have been no prospective studies to compare GPi-DBS with STN-DBS. From a retrospective perspective, a meta-analysis comparatively analyzed the results of 13 relative studies, including 58 CD patients undergoing GPi-DBS and 28 CD patients undergoing STN-DBS.[35] They found that when the factor of follow-up time was not taken into account, the improvement rates of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) subscores (severity, disability, and pain) were all significantly higher in the GPi-DBS group than that in the STN-DBS group, though the TWSTRS total score was not significantly different. Nevertheless, when the follow-up time was limited to three years, neither TWSTRS total score nor subscores showed a significantly between-group difference.[35] Similarly, another meta-analysis also failed to detect any significant difference — the improvement rates of the TWSTRS total score were 60.4% (GPi-DBS) and 56.6% (STN-DBS), respectively (p=0.936).[36] However, the two meta-analyses included low-quality studies and showed significant heterogeneity and publication bias. Surgeons still have confusion in the face of target selection before surgery. As such, a well-designed randomized controlled trial (RCT) is entailed to ascertain which one (STN or GPi) is the optimal DBS target for CD.

Objective

41 The PASTS-CD study aims to compare GPi-DBS with STN-DBS for drug-refractory CD in the

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

following aspects: (1) improvement of dystonic symptoms (severity, disability, and pain), (2)
 improvement of life quality, mental status, and cognitive status, (3) stimulation parameters, (4) adverse

2 improvement of life quality, mental status, and cognitive status, (3) stimulation parameters, (4) adverse

3 effects. In the end, the study intends to identify the potential factors that are associated with DBS

4 efficacy in both groups.

5 METHODS AND ANALYSIS

6 Study design and setting

The PASTS-CD study is an investigator-initiated, multicenter, prospective, randomized, parallel-controlled equivalence clinical trial, following the rules of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.[37] The method of minimization for randomization will be used to produce two paralleling arms with an allocation ratio of 1:1, both of which undergo the same procedures except for the difference in DBS target (GPi or STN). The flow chart of the trial is presented in figure 1. This study will be implemented from September 1, 2023 to November 30, 2026 in four tertiary hospitals in China. This study only incorporates hospitals that have been qualified in DBS surgery for more than 5 years with more than 20 DBS operations per year, and where DBS surgery-related complication rate is less than 5%. In addition, all investigators will go through a standardized training before trial initiation.

- 17 Participants
 - 18 Recruitment

The investigators will post the recruitment announcement on each center's official website and WeChat
account. CD Patients who are willing to participate in the trial will visit the dystonic outpatient of each
center.

- 22 Inclusion criteria
- 23 (1) Diagnosed as idiopathic or hereditary isolated CD;
- 24 (2) Severe functional impairment;
- 25 (3) Oral medication and injection of botulinum toxin become ineffective after at least two attempts (>
 26 6 months since last injection);
- 27 (4) No secondary causes of CD;
 - (5) Age 18-80 years old;
 - 29 (6) Normal neurological examination except for dystonia;
- (7) Normal brain MRI;
 - 31 (8) The subject or their family members can fully understand the trial and sign the informed consent;
 - **32** (9) Good compliance and willingness to receive regular follow-ups.
 - 33 <u>Exclusion criteria</u>
 - 34 (1) Diagnosed as secondary CD;
 - 35 (2) CD with obvious trunk/limb involvement, or Meige syndrome;
 - (3) History of severe mental disorders, dementia, or epilepsy;
 - 37 (4) Previous dystonia surgery (pallidotomy, thalamotomy, DBS, etc);
 - 38 (5) Accompanied by other neurological diseases (Parkinson's disease, essential tremor, multiple
 39 sclerosis, stroke, etc);
- 40 (6) The patient has or needs other implantable devices (cardiac pacemakers, defibrillators, cochlear
 41 implants, spinal cord stimulators, etc);

3 / 12

BMJ Open

1 (7) Pregnant women or women who are waiting to become pregnant during the trial;

- 2 (8) Poor health condition.
- 3 Dropout or suspension of the trial
- 4 (1) Postoperative infection that requires removal of DBS electrodes;
 - 5 (2) Severe displacement of DBS electrodes position from the predefined targets (> 3mm for STN-DBS
- 6 group and > 5mm for GPi-DBS group);

7 (3) Occurrence of severe adverse events or other serious diseases that interfere with the efficacy8 assessment;

- 9 (4) Loss to follow up;
- 10 (5) Requests from patients to withdraw from the trial;
 - 11 Interventions
 - 12 <u>Baseline evaluation</u>

For each eligible patient, the basic information, medical history, disease characteristics, and medications (especially the time and frequency of botulinum toxin injection) will be recorded in the electronic medical record system in detail. Besides, physical examination, routine blood tests, and MRI scanning are assigned before surgery. Every patient will be videotaped as per a standardized scheme (see supplementary material) without drug withdrawal. These videos will be collected and transferred to two neurological raters who will complete the TWSTRS-severity subscale and Tsui scale blindly and separately at the end of the trial. Moreover, the TWSTRS-disability subscale, TWSTRS-pain subscale, 36-item Short Form General Health Survey (SF-36), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) will also be completed before surgery. The timeline of data collection is shown in table 1. After signature of the informed consent form, candidate patients will be randomized into the GPi-DBS group or the STN-DBS group.

25 <u>DBS surgery</u>

Certain minor differences in surgical procedures are allowed among involved centers as long as the electrodes are placed safely and accurately, but some critical steps must keep in line with each other. Specifically, on the day of surgery, a stereotactic head frame is fixed on the patient's head, followed by a CT scan. The frame CT images and the preoperative MRI images $(1.0 * 1.0 * 1.0 mm^3, no gap)$ will be fused in a surgical planning system, where the coordinates of the targets and trajectories are determined. DBS electrodes are implanted with the assistance of a stereotactic frame or neurosurgical robot under general anesthesia with bi-spectral index monitoring (BIS). After completion of burr holes, microelectrode recording (MER) is monitored intraoperatively to further assist the targeting of nuclei. The dosage of propofol should be reduced on recording, keeping the value of BIS fluctuating around 70, so as not to affect neuronal discharges. [38] An eligible firing pattern should be recorded as described by Robert, et al.[39] If not, the target should be adjusted or use two- or multiple-channel recording. Passive limb movements can be helpful to identify the sensorimotor subregion of the nuclei. Given that patients are under general anesthesia and their heads are immobilized by the frame, intraoperative macrostimulation can be omitted. Subsequently, according to the randomized allocation, the corresponding quadripolar electrodes will be implanted into posteroventral GPi (GPi-DBS group) or dorsolateral STN (STN-DBS group), bilaterally. The implanted electrodes can be selected from anyone

of the following three manufacturers: Medtronic (Minneapolis, USA), PINS Medical (Beijing, China),
and SceneRay (Suzhou, China). Of note, in light of the volume difference between the two nuclei,
electrodes with contact intervals of 1.5mm are chosen for GPi-DBS, but 0.5mm for STN-DBS.
Afterwards, inserted leads will be fixed at the burr hole site and an implantable pulse generator (IPG)
will be connected and implanted at the right subclavicular area subcutaneously.

6 <u>Electrode position confirmation</u>

7 If possible, an intraoperative MRI scanning is strongly recommended to verify the implantation
8 accuracy. Otherwise, a postoperative MRI or CT scanning is compulsory before discharge from
9 hospitals. In order to exclude the effect of electrode position on the DBS efficacy, the intraopetative or
10 postoperative images are fused with the preoperative images. If the deviating Euclidean distance
11 between the lead tip and the predefined target exceeds 3mm (STN-DBS group) or 5mm (GPi-DBS
12 group), the subject will be dropped out.

13 <u>Follow-up</u>

One month later, the DSB will be activated by a specialized DBS programmer in the outpatient department. To evaluate stimulation effects and adverse effects of both electrodes, all contacts will be screened in a monopolar mode with the voltage increasing gradually from 1V to 4V and pulse width and frequency kept at 60us and 130Hz. For those whose symptoms improve rapidly, the optimal parameters will be documented and used for chronic stimulation. For those who lack an acute improvement, the activated contact is identified based on the results of MER or the 3D reconstruction of the electrodes via the Lead DBS software (the contact closest to the posteroventral GPi or the dorsolateral STN), and the voltage is set at 25% below the threshold for causing a stimulation-related adverse effect. At the 3-month follow-up, a standardized video will be recorded and TWSTRS-disability and pain subscales are completed by a centrally-trained rater. At the 6-month and 12-month follow-ups, in addition to the standardized video and TWSTRS subscales, all the other scales (i.e. SF-36, HAMA, HAMD, MMSE, and MoCA) will also be evaluated (table 1). Of note, to focus on the effect of DBS and exclude the confounding effect of medication, botulinum toxin injection is forbidden during the follow-up period, and in a week leading up to each evaluation, the patient should take the same oral drugs as before surgery. Furthermore, throughout the implementation of the trial, all adverse effects must be handled in safety and documented in detail, regardless of surgery-derived, device-related, or stimulation-induced events. Regular programming will also be performed at each follow-up to find the best parameters. The initial stimulating setting can be modulated at any time when the patients feel unsatisfactory about the symptom control or encounter a stimulation-induced adverse effect.

33 Outcome measurements

The primary outcomes are the changes (improvement rates) of the TWSTRS-severity subscale and the Tsui scale at 3 months, 6 months, and 12 months after surgery. The reason why these two scales are chosen as the primary outcomes is that both of them are obtained from standardized videos, while the TWSTRS disability and pain subscales can be acquired via questionnaires. The Tsui scale is a rational complement to the TWSTRS-severity subscale by adding the assessment of head tremor.

39 The secondary outcomes are the changes (improvement rates) of the TWSTRS-disability subscale,

40 TWSTRS-pain subscale, the difference of stimulation parameters and adverse effects at 3 months, 6

41 months, and 12 months after surgery, as well as the SF-36 questionnaire, HAMA scale, HAMD scale,

5 / 12

MMSE scale, and MoCA scale at 6 months and 12 months after surgery. The improvement rate of each scale can be calculated by the following formula: (score at each follow-up time point - baseline score) / baseline score *100%. Stimulation parameters are mirrored by the total electrical energy delivered $(\text{TEED} = \text{voltage}^2 * \text{pulse width} * \text{frequency } *1 \text{ second } / \text{impedance}).[40]$ The higher the TEED, the shorter the battery life of the stimulator. To quantify the adverse effects, the Timed Up and Go (TUG) test is used to evaluate the severity of bradykinesia (the most common adverse effect for GPi-DBS) and the Abnormal Involuntary Movement scale (AIMs) is used to estimate the severity of dyskinesia (the most common adverse effect for STN-DBS).

9 Table 1 Participant timeline of data collection.

	Enrolme	Allocatio	Post-		Follo	w-up	
	nt	n/Surgery	Surger				
TIMEPOINT	-1	0	у 1	4	12	24	48
(weeks±1)	-1	0	1	4	12	24	(Close-ou
ENROLMENT :							
Eligibility screen	x						
Informed consent	x						
Medical history	х						
MRI scanning	х		Х				
Allocation		х					
INTERVENTIONS :							
GPi-DBS surgery		x					
STN-DBS surgery		Х					
DBS				X	Х	Х	Х
ASSESSMENTS :							
Standardized video*	Х				Х	Х	Х
TWSTRS-disability	Х				Х	Х	Х
TWSTRS-pain	Х				X	Х	Х
SF-36	Х					Х	Х
HAMA	Х					Х	Х
HAMD	Х					X	Х
MMSE	Х					Х	Х
MoCA	Х					Х	Х
Medication	Х				Х	Х	Х
Stimulation				Х	Х	Х	Х
parameters							
Adverse effects		Х	Х	Х	Х	Х	Х

10 Sample size

The sample size is calculated based on one of the primary outcomes — the improvement rate of
 TWSTRS-severity subscore. According to the results of the latest meta-analysis comparing GPi-DBS
 with STN-DBS for CD treatment, the improvement rates (%) of TWSTRS-severity subscore at the same 6/12

follow-up time (3 years) were 53.7±20.4 (GPi-DBS) and 39.3±26.4 (STN-DBS), respectively.[35] Based on the model of two independent sample T test, 41 patients for each group are required to reach

- a significant level of 5% (two-tailed) with 80% power. Assuming that 5% of CD patients would be
- withdrawn from the trial and another 10% of CD patients would be lost to follow-up, a total of 98 CD
- patients are required (49 patients for each group).

Randomization and blinding

Patients will be randomly assigned (1:1) to GPi-DBS group or STN-DBS group by using a bespoke web-based randomization sequence generated by the minimization method with a random component

with gender (male or female), CD subtypes (phasic type or tonic type), and disease duration (< 3 years

or \geq 3 years) as factors of allocation adjustment. Randomization was stratified by participating centers.

A specific neurosurgeon of each center who will participate in the DBS surgery submits the basic information of the patient to the online system, and then a unique random code and grouping information will be returned automatically. Only this neurosurgeon has access to the central randomization system. Investigators (neurosurgeons) are not blinded because of the nature of the surgical intervention, but patients, scale raters, and data analysts are blinded. At the time of scale scoring and video recording, each patient wears an operating cap so that scale raters are blinded to the condition of surgery (preoperatively). All standardized videos recorded for evaluation of the TWSTRS-severity subscale and the Tsui scale will be shuffled randomly and scored twice centrally by two experienced neurologists who do not know the grouping information and time points of follow-up. The mean score values of the two neurologists will be documented and uploaded. Furthermore, before data is transferred to data analysts for statistical analysis, the data manager will mask the grouping information and set two groups as A and B instead. Only when the subjects are withdrawn would they be unblinded.

Data collection and management

The schematic chart for data collection is shown in table 1. Prior to the enrollment of the first patient, all investigators (including neurosurgeons, coordinators, scale raters, DBS programmers, data managers, etc) have to receive standardized training in data collection and management. At baseline and each follow-up time point, all information (medical history, scales, videos, programming parameters, and adverse effects) will be transferred to a coordinator who will then fill in the case report forms (CRFs). All items in CRFs have to be completed and any correction should be noted and explained. Eventually, two coordinators upload the standardized videos and input the information of CRFs into the electronic data capture (EDC) system Whole Course Management Service Platform (https://admin.demo.sdc.sinohealth.com/login).

Notably, the EDC system is linked with a patient client that can be installed on patients' or their family's mobile phones, through which, investigators can push disease-related knowledge or questionnaires (for example, SF-36) to patients and conversely, patients can submit questionnaires and express their complaints to investigators at any time. Before each follow-up time point, patients will receive an alert from this client, thereby improving follow-up compliance.

During data collection, two data monitors will audit the contents of the CRFs to ensure data authenticity and accuracy. In addition, a data manager will review the EDC data online in real-time and check the

7/12

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA

data consistency. Any data error or query existing, the data manager will send it back to the corresponding center where the investigators will check the original documents, answer the query, and update the data. At the end of the trial, the data manager will lock the EDC database and send the data to two data analysts for analysis. All data files should be managed with great care and confidentiality. Only authorized investigators can login the EDC system with a password and any modification trace on the DEC platform will be preserved. Additionally, all original scale files and CRFs will be locked in a special cabinet and all video files will be stored in an encrypted folder. **Data monitor** Any adverse events during the study period should be documented in detail, including the information of event date, category, severity, treatment, and prognosis. If severe adverse events occur, the principal investigator must be notified within 24 hours.

Two study monitors who are independent of the implementation of this trial and have no competing interests will regularly visit the participating centers to inspect the protocol adherence, recruitment status, data collection, reporting of adverse events, and subject dropout rate. The monitoring results will be presented to the principal investigator and the local ethics committee. The interim analyses are unnecessary because plenty of previous studies have confirmed the safety of DBS surgery of both targets.[7, 10, 14, 16, 17, 29] Herein, this trial only concentrates on their potential differences.

19 Statistical analysis

Outcome statistics will be performed using cases with complete data, i.e., per protocol (PP) analyses. In
 addition, for the primary outcomes, an intention-to-treat (ITT) analysis (including all patients assigned
 in the trial) will also be performed with missing values imputed by multiple interpolations.

Continuous variables will be presented as means \pm standard deviations for normally distributed data or as medians (interquartile ranges) for skewed data. Categorical variables will be presented as frequencies or percentages. For difference analyses of baseline information, this study uses the Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. Moreover, two-way ANOVA will be used to analyze the main effects (group or time) and the interaction effects. Within-group post hoc comparisons between different time points will be analyzed by paired T test or Wilcoxon signed-rank sum tests. Between-group comparisons at a certain time point will be analyzed using the Wilcoxon rank-sum test. Factors associated with DBS efficacy, such as gender, age at surgery, and disease duration, will be included as covariates.[31, 34, 41] Of note, when analyzing the adverse effects, those patients who have been withdrawn due to severe adverse effects should be included. Finally, to explore predictors of DBS outcomes, this study uses simple linear regression first to screen variables relevant to the improvement rates of TWSTRS, and multiple linear regression second to identify independent variables.

36 A difference of p < 0.05 (two-tailed) is specified as statistically significant. SPSS 26 statistical software

50 37 will be used for statistical analyses.

38 Patients and public involvement

39 Patients and the public are not involved in the design and implementation of this trial.

- 40 ETHICS AND DISSEMINATION
 - 41 The PASTS-CD trial protocol has been approved by the Medical Ethics Committee of Chinese PLA

8 / 12

General Hospital (S2022-613-01), which is also responsible for re-examining protocol modifications in
 the future, if any. Moreover, this trial has been registered on Clinicaltrials.gov (NCT05715138).

The investigators have to explain the objectives of this trial and every surgical detail to the patients or their families, and the informed consent form must be signed before allocation. For those patients with surgical sequelae, this study provides ancillary and post-trial care according to standard medical practice. The investigators have access to the final results, which will be published in international peer-reviewed journals and shared in professional medical conferences. The raw data can be available from the

8 corresponding author upon reasonable request. Patients' information will be de-identified and videos
9 will be mosaicked before exhibition.

DISCUSSION

To the best of our knowledge, the PASTS-CD study is the first prospective RCT study directly comparing the efficacy and safety of GPi-DBS and STN-DBS for refractory CD patients. The results of this trial will be a powerful guide for neurosurgeons in the selection of DBS targets for CD patients.

One notable advantage of this trial is that the primary outcomes are quantified by standardized videos centrally and blindly by two neurologists. The customized scheme of standardized video recording has been tested to suffice for the scoring of the TWSTRS-severity subscale and Tsui scale. This design will eliminate the measurement bias from different scale raters of different centers and the interviewer bias from the subjectivity of scale raters. Another advantage is that this trial controls the confounding effect of electrode implantation accuracy, which is considered to be the most relevant factor to DBS efficacy.[42, 43] Due to the small size of the subcortical nuclei and the complex surrounding structures, a minor deviation from the target will bring about a significant disparity in DBS efficacy and adverse effects. Through measuring the distance between the sensorimotor subregion of target nuclei and the contacts of electrodes, the investigators exclude those subjects in which the volume of tissue activated (VTA) of DBS electrodes is speculated to show no or a low overlapping with the sensorimotor subregion of target nuclei. According to previous experiences [44, 45] and the volume difference between the two targets, the cutoff distance is defined to be 3mm for the STN-DBS group and 5mm for the GPi-DBS group. This procedure also minimizes the influence of technical discrepancy of different neurosurgeons. One possible limitation is that the neurosurgeons are not blinded, but this is determined by the nature of the surgical intervention. In fact, the main role of neurosurgeons is implanting the DBS electrodes into the predefined subregion of the two subcortical nuclei, and they do not participate in the subsequent scales scoring and DBS programming. As such, by controlling the accuracy of electrode position, the accompanying bias from the unblinded neurosurgeons will be significantly reduced. In addition, owing to the low incidence of CD, the investigators have to initiate a multicenter study to meet the requirement of sample size. Although multicenter studies may increase heterogeneity to some extent, it is believed that strict protocol implementation, coupled with systematic training and constant study monitoring, will help to minimize the biases and maximize the reliability of results.

- 38 Author affiliations
- 39 ¹ Medical School of Chinese PLA, Beijing, China
- 40 ² Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing,

9 / 12


2			
3 4	1	China	
5	2		vledgements None
6	2	Contrib	-
7			
8 9	4	•	onception: MZQ and YXG. Initial study design: LB and XJP. Revision of study design and
9 10	5	•	: MZQ. statistical analysis: YHN. Study coordination: YXG. Drafting the manuscript: LB and
11	6		authors read and approved the final manuscript.
12	7	-	g This trial is supported by STI 2030 - Major Projects (2021ZD0200407).
13	8	Compet	ing interests None declared.
14 15	9	Patient	consent for publication Not applicable.
16	10	Provena	ance and peer review Not commissioned; externally peer-reviewed.
17	11	Data av	ailability statement Data are available upon reasonable request.
18	12	ORCID	iD
19 20	13	Bin Liu	http://orcid.org/0000-0001-5114-7350
20	14		
22	15		
23	16		References
24	17		Interenteus
25 26	18	1.	Albanese, A., Deep brain stimulation for cervical dystonia. Lancet Neurol 2014; 13(9): 856-7.
27	19		
28			Crowner, B.E., Cervical dystonia: disease profile and clinical management. <i>Phys Ther</i> 2007; 87(11):
29	20		1511-26.
30 31	21		Figgitt, D.P. and S. Noble, Botulinum toxin B: a review of its therapeutic potential in the
32	22		management of cervical dystonia. Drugs 2002; 62(4): 705-22.
33	23		Comella, C. and K. Bhatia, An international survey of patients with cervical dystonia. <i>J Neurol</i> 2015;
34	24		262(4): 837-48.
35	25	5.	Jinnah, H.A., C.L. Comella, J. Perlmutter, et al., Longitudinal studies of botulinum toxin in cervical
36 37	26		dystonia: Why do patients discontinue therapy? Toxicon 2018; 147: 89-95.
38	27	6.	Ravindran, K., N. Ganesh Kumar, D.J. Englot, et al., Deep Brain Stimulation Versus Peripheral
39	28		Denervation for Cervical Dystonia: A Systematic Review and Meta-Analysis. World Neurosurg
40	29		2019; 122: e940-e946.
41 42	30	7.	Rodrigues, F.B., G.S. Duarte, D. Prescott, et al., Deep brain stimulation for dystonia. Cochrane
43	31		Database Syst Rev 2019; 1(1): CD012405.
44	32		Vidailhet, M., L. Vercueil, J.L. Houeto, et al., Bilateral deep-brain stimulation of the globus pallidus
45	33		in primary generalized dystonia. N Engl J Med 2005; 352(5): 459-67.
46 47	34		Kupsch, A., R. Benecke, J. Muller, et al., Pallidal deep-brain stimulation in primary generalized or
48	35		segmental dystonia. <i>N Engl J Med</i> 2006; 355(19): 1978-90.
49			
50	36		Hung, S.W., C. Hamani, A.M. Lozano, et al., Long-term outcome of bilateral pallidal deep brain
51	37		stimulation for primary cervical dystonia. <i>Neurology</i> 2007; 68(6): 457-9.
52 53	38		Vidailhet, M., L. Vercueil, J.L. Houeto, et al., Bilateral, pallidal, deep-brain stimulation in primary
54	39		generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007; 6(3): 223-9.
55	40	12.	Mueller, J., I.M. Skogseid, R. Benecke, et al., Pallidal deep brain stimulation improves quality of
56			10 / 12
57 58			10 / 12
58 59			
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


1

1 2			
2	4		
4	1		life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled
5	2		trial. <i>Mov Disord</i> 2008; 23(1): 131-4.
6 7	3	13.	Volkmann, J., A. Wolters, A. Kupsch, et al., Pallidal deep brain stimulation in patients with primary
8	4		generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;
9	5		11(12): 1029-38.
10	6	14.	Moro, E., C. LeReun, J.K. Krauss, et al., Efficacy of pallidal stimulation in isolated dystonia: a
11 12	7		systematic review and meta-analysis. Eur J Neurol 2017; 24(4): 552-560.
12	8	15.	Meoni, S., V. Fraix, A. Castrioto, et al., Pallidal deep brain stimulation for dystonia: a long term
14	9		study. J Neurol Neurosurg Psychiatry 2017; 88(11): 960-967.
15	10	16.	Krause, P., S. Volzmann, S. Ewert, et al., Long-term effects of bilateral pallidal deep brain
16 17	11		stimulation in dystonia: a follow-up between 8 and 16 years. J Neurol 2020; 267(6): 1622-1631.
17	12	17.	Ostrem, J.L., C.A. Racine, G.A. Glass, et al., Subthalamic nucleus deep brain stimulation in primary
19	13		cervical dystonia. Neurology 2011; 76(10): 870-8.
20	14	18.	Zhan, S., F. Sun, Y. Pan, et al., Bilateral deep brain stimulation of the subthalamic nucleus in primary
21 22	15		Meige syndrome. J Neurosurg 2018; 128(3): 897-902.
23	16	19.	Ostrem, J.L., M. San Luciano, K.A. Dodenhoff, et al., Subthalamic nucleus deep brain stimulation
24	17		in isolated dystonia: A 3-year follow-up study. Neurology 2017; 88(1): 25-35.
25	18	20.	Deng, Z., Y. Pan, C. Zhang, et al., Subthalamic deep brain stimulation in patients with primary
26 27	19		dystonia: A ten-year follow-up study. Parkinsonism Relat Disord 2018; 55: 103-110.
28	20	21.	Cao, C., Y. Pan, D. Li, et al., Subthalamus deep brain stimulation for primary dystonia patients: a
29	21		long-term follow-up study. Mov Disord 2013; 28(13): 1877-82.
30 31	22	22.	Chung, M. and R. Huh, Different clinical course of pallidal deep brain stimulation for phasic- and
32	23		tonic-type cervical dystonia. Acta Neurochir (Wien) 2016; 158(1): 171-80; discussion 180.
33	24	23.	Kaelin-Lang, A., H. You, J.M. Burgunder, et al., Bilateral pallidal stimulation improves cervical
34	25		dystonia for more than a decade. <i>Parkinsonism Relat Disord</i> 2020; 81: 78-81.
35 36	26	24.	Volkmann, J., J. Mueller, G. Deuschl, et al., Pallidal neurostimulation in patients with medication-
37	27		refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014; 13(9): 875-
38	28		84.
39 40	29	25.	Kiss, Z.H., K. Doig-Beyaert, M. Eliasziw, et al., The Canadian multicentre study of deep brain
40	30		stimulation for cervical dystonia. <i>Brain</i> 2007; 130(Pt 11): 2879-86.
42	31	26.	Walsh, R.A., C. Sidiropoulos, A.M. Lozano, et al., Bilateral pallidal stimulation in cervical dystonia:
43	32	20.	blinded evidence of benefit beyond 5 years. <i>Brain</i> 2013; 136(Pt 3): 761-9.
44 45	33	27.	Skogseid, I.M., J. Ramm-Pettersen, J. Volkmann, et al., Good long-term efficacy of pallidal
46	34	27.	stimulation in cervical dystonia: a prospective, observer-blinded study. <i>Eur J Neurol</i> 2012; 19(4):
47	35		610-5.
48 49	36	28.	Yin, F., M. Zhao, X. Yan, et al., Bilateral subthalamic nucleus deep brain stimulation for refractory
49 50	37	20.	isolated cervical dystonia. <i>Sci Rep</i> 2022; 12(1): 7678.
51	38	29.	Gupta, A., Subthalamic stimulation for cervical dystonia. <i>Acta Neurochir (Wien)</i> 2020; 162(8):
52	39	<i>2)</i> .	1879-1881.
53 54	40	30.	Schjerling, L., L.E. Hjermind, B. Jespersen, et al., A randomized double-blind crossover trial
55	41	50.	comparing subthalamic and pallidal deep brain stimulation for dystonia. <i>J Neurosurg</i> 2013; 119(6):
56	-+ 1		
57 58			11 / 12
58 59			
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1		1537-45.
2	31.	Hock, A.N., S.R. Jensen, K.W. Svaerke, et al., A randomised double-blind controlled study of De
3		Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 year
4		Parkinsonism Relat Disord 2022; 96: 74-79.
5	32.	Liu, Y., G. Zhu, Y. Jiang, et al., Comparison of Short-Term Stimulation of the Globus Pallic
6		Interna and Subthalamic Nucleus for Treatment of Primary Dystonia. World Neurosurg 2019; 12
7		e211-e217.
8	33.	Lin, S., Y. Wu, H. Li, et al., Deep brain stimulation of the globus pallidus internus versus
9		subthalamic nucleus in isolated dystonia. J Neurosurg 2019; 132(3): 721-732.
10	34.	Wu, Y.S., L.H. Ni, R.M. Fan, et al., Meta-Regression Analysis of the Long-Term Effects of Pallie
11		and Subthalamic Deep Brain Stimulation for the Treatment of Isolated Dystonia. World Neurosi
12		2019; 129: e409-e416.
13	35.	Hua, X., B. Zhang, Z. Zheng, et al., Predictive factors of outcome in cervical dystonia followi
14		deep brain stimulation: an individual patient data meta-analysis. J Neurol 2020; 267(6): 1780-179
15	36.	Tsuboi, T., J.K. Wong, L. Almeida, et al., A pooled meta-analysis of GPi and STN deep brack
16		stimulation outcomes for cervical dystonia. J Neurol 2020; 267(5): 1278-1290.
17	37.	Chan, A.W., J.M. Tetzlaff, P.C. Gotzsche, et al., SPIRIT 2013 explanation and elaboration: guidar
18		for protocols of clinical trials. BMJ 2013; 346: e7586.
19	38.	Venkatraghavan, L., E. Rakhman, V. Krishna, et al., The Effect of General Anesthesia on t
20		Microelectrode Recordings From Pallidal Neurons in Patients With Dystonia. J Neurosu
21		Anesthesiol 2016; 28(3): 256-61.
22	39.	Gross, R.E., P. Krack, M.C. Rodriguez-Oroz, et al., Electrophysiological mapping for t
23		implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord 2006;
24		Suppl 14: S259-83.
25	40.	Koss, A.M., R.L. Alterman, M. Tagliati, et al., Calculating total electrical energy delivered by de
26		brain stimulation systems. Ann Neurol 2005; 58(1): 168; author reply 168-9.
27	41.	Isaias, I.U., J. Volkmann, A. Kupsch, et al., Factors predicting protracted improvement after pallie
28		DBS for primary dystonia: the role of age and disease duration. J Neurol 2011; 258(8): 1469-76.
29	42.	Wodarg, F., J. Herzog, R. Reese, et al., Stimulation site within the MRI-defined STN predi
30		postoperative motor outcome. <i>Mov Disord</i> 2012; 27(7): 874-9.
31	43.	Park, H.R., J.M. Lee, G. Ehm, et al., Correlation of electrode position and clinical outcomes
32		globus pallidus stimulation for dystonia. <i>Acta Neurochir (Wien)</i> 2017; 159(7): 1349-1355.
33	44.	Zhang, D., H. Lin, J. Liu, et al., Electrode Reconstruction Assists Postoperative Contact Selection
34		in Deep Brain Stimulation. <i>World Neurosurg</i> 2019; 125: e442-e447.
35	45.	Astrom, M., E. Diczfalusy, H. Martens, et al., Relationship between neural activation and elect
36		field distribution during deep brain stimulation. <i>IEEE Trans Biomed Eng</i> 2015; 62(2): 664-672.
37		
38	0	e legend
39	0	e 1 Flow chart of the PASTS-CD study. GPi, globus pallidus internus; STN, subthalamic nuclei
40	DBS,	deep brain stimulation.
40		





Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3	Scheme of Standardized Video Recording
4	1. Seated position. (The patient wears a surgical cap with head, neck and shoulders on camera.)
5	
6 7	① Eyes closed (20 seconds: 10 seconds recorded from the front and 10 seconds from the side).
8	Say to the patient, "Please sit down, close your eyes, and put your head where you feel most
9	comfortable."
10	2 Eyes open (10 seconds: 5 seconds recorded from the front and 5 seconds from the side).
11	Say to the patient, "Please sit down, open your eyes, and try to look straight ahead and keep your
12	head in the middle."
13 14	③ Turn head right and turn head left (5 seconds each)
15	Say to the patient: "Look forward to the camera, turn your head to the right as far as you can, and
16	
17	then turn your head to the left as far as you can."
18	④ Head up and head down (5 seconds each)
19	Say to the patient: "Look forward to the camera, raise your head as high as you can, and then
20 21	lower your head as low as you can."
22	\bigcirc Put the ear close to the right shoulder and then the left shoulder (5 seconds each).
23	Say to the patient, "Look forward to the camera. Now bring your right ear as close to your right
24	shoulder as possible, and do not move your right shoulder."
25	Say to the patient, "Look forward to the camera. Now bring your left ear as close to your left
26	shoulder as possible, and do not move your left shoulder."
27	
28 29	6 Symptom persistence
30	Ask the patient, "If you divide your awake time during the day into four equal parts, how many
31	parts do neck abnormalities take up?"
32	⑦ Symptom characteristics
33	Ask the patient, "Does each episode come on suddenly or gradually?"
34	(8) Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds)
35 36	Say to the patient, "Please try to put your head in a straight position and look forward to the
37	camera for one minute. Now start the clock."
38	
39	
40	Say to the patient, "Rest for 10 seconds."
41	⁽¹⁾ Anterior view (Stop timing until the head is 10 degrees off center. Up to 60 seconds)
42 43	Say to the patient, "Please do it again. Try to put your head in a straight position and look forward
44	to the camera for one minute. Now start the clock."
45	(1) Sensory tricks
46	Say to the patient, "Are there some movements or postures you can do to straighten your head? If
47	so, try to do it."
48	•
49 50	2. Standing position (Show the whole body)
51	① Anterior view (5 seconds)
52	Say to the patient, "Please stand up and face the camera."
53	2 Lateral view (5 seconds)
54	Say to the patient, "Please turn 90 degrees to the left (or right)."
55	3. Walking (10 seconds)
56	Say to the patient, "Please walk forward to the door and turn back."
57 58	
59	

Checklist

		Reporting Item	Page Num
Administrative information			
Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Title Page
Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	1, 8
Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	<u>#3</u>	Date and version identifier	Title Page
Funding	<u>#4</u>	Sources and types of financial, material, and other support	9
Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	Title Page, 9
Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	n/a (no sponsor)
Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a (no sponsor)
Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n/a
Introduction			
Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	1-2

BMJ Open: first published as 10.1136/bmjopen-2023-073425 on 13 October 2023. Downloaded from http://bmjopen.bmj.com/ on May 21, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

$1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 40 \\ 41 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	1
	Objectives	<u>#7</u>	Specific objectives or hypotheses	2-3
	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	3
	Methods: Participants, interventions, and outcomes			
	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	3
	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	3
	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	4-5
	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	4
	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7
42 43 44	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	5
45 46 47 48 49 50 51 52 53 54 55 56 57 58	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	5
	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5-6
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 2 3 14 15 16 7 18 9 0 2 1 2 2 3 2 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 11 2 3 2 4 5 6 7 8 9 0 11 2 3 2 4 5 6 7 8 9 0 11 2 3 2 4 5 6 7 8 9 0 11 2 3 2 4 5 6 7 8 9 0 11 2 2 3 2 4 5 6 7 8 9 0 11 2 2 3 2 4 5 6 7 8 9 0 11 2 2 3 2 4 5 6 7 8 9 0 11 2 2 3 2 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	3
	Methods: Assignment of interventions (for controlled trials)			
	Allocation: sequence generation	<u>#16a</u>	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6
	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6
	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6
	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7
	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	7
	Methods: Data collection, management, and analysis			
	Data collection plan	<u>#18a</u>	other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5-6, 6-7
60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7 BMJ Open: t
	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7 7 7 7 8 Protected by copyright, including for uses related to text and date of the text and date of the text and text
	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	as 10.1136/bmjopen-2023-073425 on 13 October 20 Erasn Protected by copyright, including for uses related
17 18 19 20	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	-2023-073 ght, inclu
21 22 23 24	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	425 on 13 Oc ding for uses 8
25 26 27	Methods: Monitoring			tober: Eras relate
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a smushogeschool - This trial sets two study mornitors data mining, A of DMC.
	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a Al training No interim analysesing, and (Page 7-8) and
	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	 (Page 7-8) and similar technologies 7 7 7
	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a Vitraining, and similar technologies. (Page 7-8) 7 7 8
	Ethics and dissemination			Departm
	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	8
59 60		For peer	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Þ

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	8
	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	8
19 20 21 22	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	9
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 45 56 57 58	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	8
	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	8
	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	n/a
	Dissemination policy: reproducible research Appendices	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
	Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary materials
	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
59 60		For peer	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	